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1  Introduction 
1.1 Pulmonary Emphysema  
Chronic obstructive pulmonary disease (COPD) is defined by slowly progressive 
development of airflow limitation (1). COPD is a major and increasing global health 
problem. It is predicted by the World Health Organization (WHO) to become the third 
most common cause of death and the fifth most common cause of disability in the 
world by 2020 (2). Indeed, in the United States, COPD is already the fourth most 
common cause of death and the only common cause of death that has increased 
over the last 30 years (3). Cigarette smoking is by far the most common cause of 
COPD but only a fraction of the smoking population develops this complication. 
Exposure to air pollution particles, occupational exposure to dust and fumes, and, in 
the developing world, exposure to biomass fuel used for cooking are also believed to 
be etiologic agents of COPD (4). In addition, genetic susceptibility factors must also 
contribute to the development of the disease (5). The two most common conditions of 
COPD are chronic bronchitis and pulmonary emphysema. Pulmonary emphysema is 
referred to as a pulmonary inflammatory disease in which destruction of the lung's 
gas-exchange structures, i.e. the alveoli or distal airspaces, lead to inadequate 
oxygenation, disability and frequently death (6). Such damage to the alveoli results in 
permanent "holes" in the tissues of the lower lungs and is thought to be irreversible. 
Emphysematous lung destruction reduces maximal expiratory airflow by decreasing 
the elastic recoil force that drives air out of the lungs. The present treatment of COPD 
consists of daily administration of bronchodilaters and or/steroids and oxygen 
supplimentation, often continuously for 24 hour for hypoxemic patients, however 
there are no drugs specifically developed so far that are able to cure emphysema. 
1.1.1 Historical background 
The physiologic and clinical concepts of pulmonary emphysema were developed in 
the 19th century; however the disease had been recognized as a pathologic entity 
long before following some of the earliest finding to describe emphysema that include 
for example, Bonet’s description of voluminous lungs in 1679 (7), Ruysch’s 
description and illustration of large air spaces in lung specimens of humans in 1721 
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(8) and Morgagni’s description of 19 cases in which the lungs were turgid, particularly 
from air in 1769 (9). Matthew Baillie first provided the clear illustration and description 
of emphysema as enlarged air spaces in 1799 and 1807, and pointed out its 
essentially destructive characters (10-11). A French physician, Laënnec described 
emphysema as marked variations in the size of the air “vesicles”, which might be 
smaller than a millet seed or as large as a cherry stone. He suggested that “vesicles” 
of the latter size were produced by the coalescence of adjacent air spaces following 
rupture of the alveolar walls (12-13).   
 
Later in year 1892, Osler generated a report in the Textbook of Medicine about 
idiopathic emphysema. According to him, substantive or idiopathic emphysema is a 
well marked clinical affection, characterized by enlargement of the lungs due to 
distention of the air “cells” and atrophy of their walls, and clinically by imperfect 
aeration of the blood and more or less marked dyspnea (14).  
 
In 1956, McClean suggested that emphysema is a chronic destructive lung disease, 
characterized by enlargement of existing airspaces in the lung parenchyma (15). In 
1960s, both the World Health Organisation (WHO, 1961) and the American Thoracic 
Society (ATS, 1962) defined emphysema as a condition of the lung characterized by 
permanent enlargement of airspaces distal to the terminal, non-respiratory bronchiole 
accompanied by destruction of respiratory tissue (16-17). Subsequently, a workshop 
convented by the National Heart, Lung, and Blood Institute (NHLBI) defined tissue 
destruction in emphysema as non-uniformity in the pattern of respiratory enlargement 
so that the orderly appearance of the acinus and its components is disturbed and 
may be lost (6). The acinus is the functional unit of the lung which consists of a 
respiratory bronchiole and its alveolar ducts as well as alveolar sacs, and is involved 
in gas exchange.  
1.1.2 Pathological definition and classification  
Pulmonary emphysema is anatomically defined as the "abnormal permanent 
enlargement of the airspaces distal to the terminal bronchioles, accompanied by 
destruction of their walls" (18). Both anatomical aspects can be assessed using 
quantitative histopathology, which revealed airspace enlargement (19, 20) and loss 
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of distal lung tissue, as reflected by a significant loss of total alveolar surface area 
and total capillary length (21).  
 
On the basis of acinus destruction, mainly two forms of emphysema with distinct 
morphologic and functional entities have been described so far, i.e. centrilobular (or 
centriacinar) emphysema (CLE) and panlobular (or panacinar) emphysema (PLE) 
(22, Fig.1). CLE is more common in patients who are cigarette smokers with the main 
site of destruction and inflammation being the respiratory bronchiole. In this form of 
emphysema, lesions occur more frequently in the upper than in the lower lobes of the 
lung. PLE is a type of emphysema which is not usually linked with cigarette smoking 
(23), and is generally associated with deficiency of A1AT (24) which prevents the 
function of neutrophil elastase by binding to it to produce an inactive complex and 
hence protects the respiratory regions.  In this form of emphysema, the destruction of 
the alveolar walls occurs in a fairly uniform manner, i.e. it involves all the components 
of the acinus uniformly, and as a result involves the entire lobule. Lower lobes are 
more frequently affected in this form of emphysema than are the upper lobes. 
Additionally, Saetta and co-workers suggested that smokers with CLE have more 
abnormal and narrower small airways, and airflow limitation is correlated with the 
small airway abnormalities and not with the loss of elastic recoil. By contrast, patients 
with PLE have much less severe airway abnormalities, and airflow limitation seems to 
be due to the loss of elastic recoil (25). Studies have shown that patients suffering 
from the PLE form have higher lung compliances and PLE exhibits little relation to 
peripheral airway inflammation while patients with CLE have a higher degree of 
hyperreactivity and airway inflammation which reflects the distinctive mechanical 





























Figure 1 - Schematic representation of centrilobular emphysema (CLE) and 
panlobular emphysema (PLE) in contrast to healthy lung acinar architecture (A). In 
CLE (B), respiratory bronchioles are predominantly involved, whereas in PLE (C), 
destructive enlargement of all air spaces distal to the terminal bronchiole is seen and 
the acinus is uniformly affected. AD-Alveolar duct; AS-alveolar sac; RB1-3-respiratory 
bronchiole; TB-terminal bronchiole [Picture is modified after Turato et al (27)].   
1.1.3 Pathogenesis of emphysema 
Multiple pathogenetic mechanisms contribute to the development of emphysema. No 
single mechanism can account for the complex pathology leading to destructive 
processes in emphysema. Over the past 50 years, our understanding of the 
pathogenesis of emphysema has advanced significantly, and new concepts continue 
to emerge. The critically important pathophysiological processes that interact in the 
periphery of the lung in emphysema are discussed below: 
1.1.3.1 Inflammation and emphysema 
It has been shown that chronic exposure to cigarette smoke leads to chronic 
inflammatory responses, which potentially cause alveolar destruction with an 
increase of inflammatory cells such as neutrophilic granulocytes (28-29), 
macrophages (30-33), CD8+T lymphocytes (34) and dendritic cells (35-36). These 
cells are capable of releasing inflammatory mediators and proteinases, which are 
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believed to play a role in the progressive lung destruction in emphysema. (For the 
schematic representation of pathogenesis of emphysema, see Fig.2)   
Role of neutrophilic granulocytes 
The neutrophilic granulocyte (or neutrophil) was the first inflammatory cell implicated 
in the pathogenesis of emphysema (37-38). Neutrophils release a multitude of 
mediators and tissue degrading enzymes including neutrophil elastases, proteinase-
3, and oxidants causing chronic inflammation and tissue destruction (39-40). 
Increased numbers of activated neutrophils are found in sputum and BAL fluid of 
patients with COPD (37) while some reports have failed to find any correlations 
between neutrophil numbers in tissue sections and the severity of lung destruction 
(38) (Fig.2).   
Role of alveolar macrophages  
The second major cell type involved in the pathophysiology of COPD is the alveolar 
macrophage, which was noticed to be markedly increased in numbers (5- to 10-fold) 
in airways, lung parenchyma, BAL fluid, and sputum in patients with COPD. A 
mophometric study conducted by Retamales and co-workers revealed a 25-fold 
increase of the numbers of macrophages in the tissue and alveolar space of 
emphysema patients in comparison to smokers with normal lung function (30). 
Furthermore, alveolar macrophages release increased levels of inflammatory 
mediators including cytokines as e.g., interleukin-1β (IL-1β), tumor necrosis factor-
alpha (TNF-α) and IL-6; and chemokines as e.g., IL-8, growth-related oncogene-α 
(GRO-α), macrophage inflammatory protein (MIP-1α), interferon-gamma inducible 
protein (IP-10), monokine induced by interferon-gamma (Mig) as well as the anti-
inflammatory cytokines IL-10 and leukotriene (LTB4) (41-46). IL-8, GRO-α, MIP-1α 
and LTB4 are potent chemoattractants of neutrophils whereas IP-10 and Mig have 
the capacity to attract CD8+T lymphocytes (Fig.2).   
Role of lymphocytes and dendritic cells 
Increased numbers of lymphocytes such as CD4+ and CD8+ T-cells are also thought 
to contribute to the pathogenetic mechanisms underlying COPD (47-48). Although 
increased numbers of CD8+ T-cells than CD4+ T-cells are found in the airways of 
COPD patients (47), the mechanism by which CD8+ T-cells and, to a lesser extent, 
CD4+ T-cells accumulate in the airways and lungs of patients are not yet understood. 
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The airways contain a rich network of dendritic cells, which play a crucial role to 
activate a variety of other inflammatory and immune cells including macrophages, 
neutrophils, T and B lymphocytes (49). An increase in the number of dendritic cells 
has been evaluated in rat lungs exposed to cigarette smoke (50), and in the airways 
and alveolar walls of smokers (35-36). It therefore likely that the dendritic cells may 
play an important role in the progression of emphysema in response to cigarette 
smoke and other inhaled noxious agents (Fig.2).   
1.1.3.2 Proteases/Anti-proteases and emphysema 
Proteases are a large group of enzymes that conduct proteolysis, that is, begin 
protein catabolism by hydrolysis of the peptide bonds that link amino acids together 
in the polypeptide chain. The central concept of protease/anti-protease imbalance 
hypothesis consists of switching on proteases due to inactivation of anti-proteases, 
which leads to the destruction of connective tissue components, particularly elastin, 
with ensuing development of emphysema. This concept derives from early clinical 
observations that subjects deficient in alpha1-antitrypsin (A1AT), a major circulating 
inhibitor of neutrophil elastase (51), develop severe emphysema. Takubo et al (52) 
and Cavarra et al (53) reported that pallid mice, which are naturally deficient in A1AT, 
developed emphysema earlier than strains with normal A1AT levels.  
 
Several serine proteases such as neutrophil elastase (NE), proteinase-3 and 
cathepsin-G had been found to be involved in the progression of emphysema in 
experimental animals (54). A study performed by Shapiro and co-workers (55) 
showed that mice lacking NE were 59% protected against emphysema which 
supports a role of NE in the pathogenesis of emphysema. 
  
Similarly, matrix metalloproteinases (MMPs) and cysteine proteases have also been 
observed in the lung in COPD (56-58). MMPs are a large family of zinc-dependent 
proteinases that regulate the turnover of extracellular matrix components (ECM) (59). 
Previous reports have demonstrated increased expression of MMP-1 (collagenase) 
and MMP-9 (gelatinase B) in BAL concentrations and in macrophages of 
emphysema patients (60-62). Some studies have shown the involvement of MMP-12 
in the sputum, BAL, bronchial biopsies and peripheral lung tissue of patients with 
advanced emphysema as well (63-65).  
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Several lysosomal cysteine proteases (cathepsins) as e.g., cathepsins B, S, K, and L, 
which are expressed in alveolar macrophages, comprise potent elastolytic activity 
and hence might be involved in the pathogenesis of emphysema (66-67) (Fig.2). 
1.1.3.3 Oxidants/Anti-oxidants and emphysema 
Oxidative stress is caused by an imbalance between the production of reactive 
oxygen and a biological system's ability to readily detoxify the reactive intermediate. 
Oxidative stress is thought to be implicated in the pathophysiology of emphysema. In 
the lung, oxidants that come from cigarette smoke may cause oxidative damage to 
lung matrix components such as elastin and collagen and may lead to impairment of 
elastin synthesis and repair, resulting in emphysema (68-69).   
 
Cigarette smoke is a complex mixture of >4,700 chemical compounds and is 
characterized by high concentrations of free radicals and other oxidants in both the 
gas and tar phases (70). The gas phase of cigarette smoke contains approximately 
1015 radicals per puff including reactive oxygen species (ROS), epoxides, peroxides, 
and nitrogen dioxide. The tar phase of cigarette contains more stable radicals, such 
as the semiquinone, which can react with oxygen to produce superoxide anion (O2-), 
the hydroxyl radical, and hydrogen peroxide (70).  
 
Activated inflammatory and structural cells including neutrophils, eosinophils, 
macrophages and epithelial cells in the airways of emphysema patients further 
enhance the production of ROS in excess of their antioxidant defence mechanism to 
create oxidative stress (71). This oxidative stress may further participate in several 
processes including inactivation of A1AT by oxidizing methionine residue at its active 
site, leading to an acceleration of the breakdown of elastin in lung parenchyma (72-
73). Apart from A1AT, another major inhibitor of neutrophil elastase is secretary 
leukoprotease, which can also be inactivated by oxidants (74-75). 
 
Oxidative stress serve to activate the transcription factor such as NFkB and 
transcription factor activator protein-1 (AP-1) leading to increased release of many 
inflammatory mediators including cytokines IL-8, TNF-α, and nitric oxide (NO) thus 
resulting in amplification of inflammatory response (76-77) (Fig.2). 
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1.1.3.4 Alveolar cell apoptosis and emphysema 
Initially an American pathologist, Averil Liebow, suggested that the loss of endothelial 
cells which are major structural cells of the alveolar wall, may lead to the 
development of emphysema (78). In support of this, Aoshiba and Nagai further 
discussed the concept of alveolar cell destruction due to apoptosis leading to 
emphysema (79). A year later the first documentation of lung cell apoptosis revealed 
that COPD lungs exhibited an enhanced number of TUNEL-positive cells, 
predominantly involving endothelial cells when compared with normal or non-COPD 
smoker’s lungs (58). Aoshiba and Nagai in their further study demonstrated that 
administration of active caspase-3 (an apoptosis mediator (80) induces 
interpulmonary apoptosis as well as enhanced elastolytic activity in BAL leading to 
emphysema (81). Kasahara and co-workers first described the relationship between 
VEGF, endothelial cell apoptosis, and emphysema. These authors reported that 
blocking of the VEGF receptor due to the presence of a VEGF receptor kinase 
inhibitor in rat model, induced alveolar septal cell apoptosis and led to enlargement of 
the airspaces (82). A similar outcome was noticed by Tsao et al, who reported that 
mice over-expressing placental growth factor (PIGF) also developed VEGF-
deficiency, thereby causing alveolar septal apoptosis, and emphysema (83). 
Furthermore, evidence of the concept that apoptosis could initiate airspace 
enlagement was also provided by signal transducer and activator of transcription-3 
(STAT-3)-deficient mice that were shown to develop emphysema with evidence of 
apoptosis and caspase-3 expression when infected by adenovirus (84). STAT-3 
plays a critical role in the regulation of various biological processes, including cell 
survival, apoptosis, inflammation, and proliferation.  
Additionally, increased number of CD8+T lymphocytes in the lungs of COPD patients 
could cause apoptosis of alveolar epithelial cells through the release of perforins, 




























Figure 2 - Schematic representation of pathogenesis of emphysema. A) 
Inflammation process, B) protease release in excess of their inhibitors, C) oxidatitive 
stress by cigarette smoke and inflammatory cells, and D) apoptosis process. GRO-α 
= Growth-related oncogene-α; IL-8 = interleukin-8; IP-10 = interferon-gama inducible 
protein; LTB4 = leukotriene; Mig = monokine induced by interferon-gama; MIP-1α = 
macrophage inflammatory protein; NFκB= nuclear factor kappa B; TNF-α = tumor 
nacrosis factor-α.  
1.1.4 Animal Models of Emphysema 
Animal models are especially important for slowly progressing diseases such as 
emphysema and have a major impact on the investigation of the key mechanisms in 
the pathophysiology of emphysema (87). They would also facilitate the exciting 
prospect of treatment of disease for which there is currently no effective therapy.  
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1.1.4.1 Cigarette smoke-induced emphysema model 
Cigarette smoking is a major environmental factor that predisposes patients to 
pulmonary emphysema. A variety of mammalian species have been exposed to 
cigarette smoke over the years to develop emphysema in dogs, rabbits, guinea pigs, 
and rodents (88-89). Out of these animals, Wright and colleagues reported that 
perhaps guinea pigs are the most susceptible species to cigarette smoke. In their 
study, they demonstrated that exposure of guinea pigs to tobacco smoke resulted in 
emphysema-like airspace enlargement within a few months (90). Other than guinea 
pig, several strains of mice have been described to develop emphysema after 6 
months or longer exposure to cigarette smoke (91, 52-53). A clear cut comparison 
between mice (strain B6C3F1) and rat (strain F344) in order to develop emphysema 
in response to tobacco smoke exposure was conducted by March TH and colleagues 
(92). In their study, they revealed that B6C3F1 mice are more susceptible than F344-
rats using morphometry and histopathology parameters to assess and compare 
emphysema. Guerassimov and co-workers compared five different strains of mice 
that were exposed to smoke for 6 months (93). They reported that only the AKR/J 
strain had significant emphysema, whereas A/J, SJL, and C57BL6/J strains appeared 
to be mildly susceptible to smoke and NZWLac/J stain was resistant. This study 
clearly points out towards the importance of genetic factors in determining individual 
susceptibility to cigarette smoke induced emphysema (93). The one important 
disadvantage of these models is that production of either emphysema or small airway 
remodeling takes months of smoke exposure (usually in the order of 6 months) and 
thus, is an expensive and time consuming proposition. However, the most important 
limitation of smoke models, no matter what species is selected and no matter how 
long animals are exposed, is that the disease they produce is mild, probably 
equivalent to human Global Initiative on Chronic Obstructive Lung Disease (GOLD) 
stage 1 or 2 disease (94-95). 
1.1.4.2 Elastase-induced emphysema model 
The elastase instillation based animal model is one of the fastest and easiest models 
available for emphysema. First, in 1965, Gross and colleagues reported that the 
exogenous application of a plant protease, papain, via intratracheal instillation 
destructs the elastin network in the lung and thereby leads to emphysematous like 
lesions in hamster (96). This finding enormously attracted investigators to develop 
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elastase-based emphysema animal models in the laboratory because of the following 
reasons: a) it is relatively simple to perform, b) highly reproducible and c) models 
could be created by a single treatment with an inexpensive reagent in a short period 
of time with less labour as compared to cigarette smoke exposure. A variety of 
proteases (leukocytic proteases, porcine pancreatic elastase, cysteine proteinases), 
applied via a single intrapulmonary challenge, cause an efficient enzymatic induction 
of emphysema (88, 97-100). One of the key findings in this regard was that only 
enzymes that could degrade intact elastin, an elastic fibre that together with collagen 
determines the mechanical properties of connective tissue, produced emphysema. 
The administration of porcine pancreatic elastase (PPE; 1 to 4 mg/kg), for example, 
has produced the most consistent and impressive airspace enlargement alonge with 
the loss of gas exchange area in rodents, guinea pigs, dogs, and primates followed 
by inflammatory cells accumulation within the lungs (99, 101). PPE is a compact 
gobular protein of a single polypeptide chain of 240 amino acids cross-linked by four 
disulfides bridges and breaks down elastin. PPE also offers the advantages of being 
cheap and easy to obtain. Elastase-induced emphysema remains a useful model of 
pulmonary emphysema since it replicates many aspects of the disease and facilitates 
the assessment of the efficacy of therapeutic agents, particularly those with the 
capacity to repair lung damage, a critical need in the field. 
1.2 Keratinocyte growth factor (KGF) 
Keratinocyte growth factor (KGF), also known as fibroblast growth factor-7 (FGF-7), 
was first purified from the human embryonic lung fibroblast cell line by Rubin et al 
(102). KGF consists of a single polypeptide chain of 26-28 kDa and has heparin-
binding capability (103-104). KGF is a potent mitogen for different types of epithelial 
cells and assists in repair of the skin, cornea and gastrointestinal lining by stimulating 
cells to divide and grow (105-107). In vitro and in vivo studies revealed that various 
types of mesenchymal cells produce KGF including fibroblasts (102), smooth muscle 
cells (108), micro vascular endothelial cells (109), and γδT cells obtained from skin 
and intestine(110). 
 
KGF is a member of the fibroblast growth factor (FGF) family of proteins. FGFs family 
comprise at least 23 structurally related polypeptides, commonly identified as FGF-1 
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to 23 (111) and are involved in various biological processes, for instance, 
angiogenesis, wound healing, tumorigenesis and developmental and morphogenetic 
processes (112-115). Members of the FGF family bind to a variety of FGF receptors, 
which belong to tyrosine kinase receptor family. Currently, at least four FGF 
receptors (FGF receptor 1-4) (116-118) have been discovered and are composed of 
an extracellular ligand-binding domain that contains three immunoglobulin-like 
domains (D1-D3), a transmembrane domain, and a cytoplasmic domain which bears 
the tyrosine kinase activity (119-120). Unlike other members of FGF family that can 
bind to several FGFRs, KGF binds only to a splice variant of FGFR2 termed FGFR2-
IIIb or KGFR (121), which is specifically expressed in epithelial cells and has intrinsic 
tyrosine kinase activity (122-123). KGFR differs from FGFR2 in the carboxyl-terminal 
half of D3 that is encoded by the alternatively spliced exon IIIb whereas in FGFR2 
this region is encoded by exon IIIc. While FGFR2 binds FGF-1 and FGF-2 with high 
affinity and does not interact with the KGF, KGFR binds FGF-1 and FGF-7 with high 
affinity and FGF-2 with a 20-fold lower affinity (124-125).  
1.2.1 Role of KGF in alveolar repair and maintenance 
The restoration of healthy alveolar epithelium requires the proliferation and migration 
of alveolar epithelial type 2 cells (AE2) and their differentiation into alveolar epithelial 
type 1 cells (AE1). This mechanism is crucial to the effective repair of the alveolus 
after injury. Moreover, the proliferation and migration of lung fibroblasts which are 
believed to be cells crucial for the maintenance of interstitial tissue within lung occur 
early after lung injury and are necessary for ongoing lung healing. These 
mesenchymal cells have been shown to control proliferation and differentiation of 
alveolar epithelial cells through the secretion of soluble mediators such as 
keratinocyte growth factor (KGF). 
 
Recombinat human keratinocyte growth factor (rHuKGF), also known as palifermin, is 
a modified version of naturally occurring KGF produced in Escherichia coli by 
recombinant DNA technology. Exogenous rHuKGF consists of a polypeptide chain of 
16.3 kDa and differs from endogenous human KGF in that the first 23 N-terminal 
amino acids have been deleted to improve protein stability. Administration of 
exogenous rHuKGF has been demonstrated to stimulate hyperplasia of alveolar 
epithelial type 2 cells (Fig.3) and bronchial epithelial cells, a process that resembles 
                                                                                      
 19 
the normal repair process after acute alveolar epithelial injury, as assessed by in vitro 
and in vivo studies (126-128). This role of exogenous rHuKGF of enhancing the 
spreading and motility of alveolar epithelial cells suggests that improved alveolar 
repair may underlie some of the protective effects of rHuKGF in lung injury models.  
 
The first study on the protective effect of exogenous KGF in a rodent model with 
acute lung injury (ALI) was demonstrated by Panos and co-worker (129). They 
reported that intratracheal administration of rHuKGF stimulated AE2 cells proliferation 
in vivo and reduced hyperoxia-induced lung injury in rats. Subsequently, exogenous 
KGF has been extensively explored to protect lung against experimental lung injury 
including bleomycin (130-131), Pseudomonas aeruginosa pneumonia (132), 
hydrochloric acid (133-134), oleic acid (135), and radiation and bleomycin induced 
lung injury (136). Additionally, exogenous rHuKGF may have many other beneficial 
effects on acute lung injury that include scavenging of reactive oxygen species and 
increased DNA repair (137-138). In vitro and in vivo studies have shown that 
exogenous KGF increases alveolar epithelial fluid transport in both the uninjured and 
the injured lung by up-regulating the expression of sodium pumps, primarily the Na+-
K+-ATPase alpha 1-subunit (139-140), and stimulates the production of lamellar 
bodies and expression of surfactant proteins (126, 141).  
 
Moreover, KGF has been implicated as an important factor to stimulate the lung 
epithelial wound closure involving lung epithelial cells spreading, migration, and 
proliferation (142). Furthermore, the pattern of expression of KGF and its receptor 
suggests an important role for KGF in mediating mesenchymal–epithelial interactions 
and has been implicated to play a critical role in early lung branching morphogenesis 
(143). Many organs, including lung, are composed of two primary tissue layers, 
namely, epithelium and mesenchyme. In embryonic organs such as lung which are 
formed by a process of progressive branching of the epithelium, interactions of these 
two tissues have been demonstrated to play a determining role in the formation of the 
organ’s characteristic morphology (144). KGF has been demonstrated to be 
important for early postnatal alveolarization in rats as treatment of lungs with 
neutralizing antibodies to KGF lead to inhibition of alveoli-forming secondary crests, 
resulting in a significantly reduced alveolar number (145). KGF enhanced 
compensatory lung growth after trilobectomy in rats, which was associated with an 
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increase in alveolar epithelial cell proliferation (146). Compensatory lung growth is 
achieved in part by formation of new alveoli and comprises all components of the 
alveolar septal wall, i.e. epithelium, endothelium, and interstitial tissue. 
 
 





Figure 3 - Schematic diagram shows the progression of alveolar epithelial type 2 
cells (AE2) hyperplasia in the lung after a single intratracheal injection of rHuKGF. 
[Picture is modified after Ulich et al. (126)] 
1.3  Other growth factors implicated in alveolar repair and 
maintenance 
Growth factors are diffusible proteins that act within a short distance of where they 
are produced to mediate tissue interactions. Growth factors are the key controller of 
repair and regulate a variety of cellular functions in lung that are critical for 
reestablishment of normal lung architecture.  
 
Transforming growth factor β-1 (TGFβ-1) is a member of a family that regulates cell 
proliferation, differentiation, transformation as well as extra cellular matrix 
composition and remodling. TGFβ-1 is produced by various cell types including AE2 
cells (147). It is particularly critical for induction of elastin gene expression (148) and 
formation of the elastin scaffold of alveoli (149), which was suggested to be the 
driving force for alveolarization (150). Disruption of TGFβ-1 signaling at various levels 
resulted in the development of emphysema-like phenotypes in mice (151-152). 
TGFβ-signaling is initiated by binding of TGFβ ligands to the two serine/threonine 
kinases receptors. The active form of TGFβ binds to type 2 TGFβ receptor (TGFβ-R-
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2, or TβRII), which then complexes with a type 1 TGFβ receptor (TGFβ-R-1 or 
activin-like kinase [ALK5] or Acvrl1 or ALK-1 [activin receptor like kinase 1]) (153). 
The type 1 receptor transmits signals within the cell by means of specific intracellular 
signals mediators, called smad proteins and finally, nuclear translocation and 
regulation of gene transcription occurs. 
 
TGFβ-2 transcript, one of the three isoform of TGFβ family, has been found 
exclusively in the endodermal bronchiolar epithelium and is expressed at high levels 
during normal murine lung morphogenesis (154). It has been shown that mice with 
targeted disruption of the TGFβ-2 gene died around birth due to respiratory failure 
(155). 
 
Vascular endothelial growth factor (VEGF), a heparin binding protein, is highly 
specific mitogen for vascular endothelial cells. VEGF is integral for endothelial cell 
migration, proliferation, and survival (156). As the vast pulmonary capillary bed in the 
lung is crucial in allowing efficient gas exchange to occur between the alveoli and 
circulating blood supply, this angiogenic growth factor is essential for the 
development and maintenance of the pulmonary vasculature. Furthermore, during 
alveolarization process, VEGF contributes to the extensive vascular growth of lung 
which involves the formation of new blood vessels from endothelial cells within the 
mesenchyme (157).  
 
VEGF exerts its biological effect on capillary endothelium cells through 2 specific 
tyrosine-kinase transmembrane receptors, VEGFR1 or fms-related tyrosine kinase-1 
(Flt-1) and VEGFR2 or kinase domain receptor (KDR) or fetal liver kinase-1 (Flk-1) 
(158). VEGFR2 is thought to be the main signaling receptor (159), and VEGFR1 has 
been speculated to function as a decoy receptor (160). Both of these receptors were 
initially thought to be largely confined to the capillary endothelial cells, but studies in 
animal and developing human lung confirm expression in lung tissue on activated 
macrophages and respiratory epithelial cells (161). Furthermore, VEGF signaling play 
a pivotal role during airway growth as the lung progressively acquires a rich blood 
supply through the growth of endothelial cells in the pulmonary mesenchyme which is 
crucial for the gas exchange function of the human lung. Injury and loss of this tissue 
contributes to the pathology of many forms of lung diseases.  
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Hepatocyte growth factor (HGF) was originally purified and cloned as a potent 
mitogen for mature hepatocytes (162). HGF is a multifunctional heterodimeric protein 
that is synthesized by a variety of lung cell types, including fibroblasts, alveolar 
macrophages, smooth muscle cells and epithelial cells (163). HGF has potent 
mitogenic and morphogenic activities on a wide variety of epithelial cells, including 
alveolar and bronchial epithelial cells (164-165). HGF has capacity to promote 
survival of endothelial cells and favors angiogenesis (166).  
 
Platelet-derived growth factor (PDGF) was originally isolated from blood platelets as 
a growth factor for smooth muscle cells, fibroblasts and glial cells. The critical role of 
platelet-derived growth factor-alpha (PDGF-A) in lung structure maintenance is 
supported by the findings that a proportion of mouse PDGF-A null mutants (PDGF-A-
/-) survive birth and develop generalized lung emphysema, involving the complete 
loss of alveolar smooth muscle cells (SMC) (167). Such cells are embedded in elastin 
fibres and normally build up the sphincter-like structures (alveolar ring muscles) 
around the openings of alveoli into alveolar ducts (168). The absence of alveolar 
SMC in PDGF-A-/- mice coincided with the loss of septal elastin deposits and failure 
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2 Aim of the study   
Pulmonary emphysema is one of the most important causes of morbidity and 
mortality in our modern society. Alveolar destruction is the main morphological aspect 
of pulmonary emphysema that traditionally had been viewed as irreversible and 
irreparable. To date, there is no curative therapy available that can restore functional 
lung parenchyma that has been lost in an emphysematous lung. Recombinant 
human keratinocyte growth factor (rHuKGF) is known to enhance the regenerative 
capacity of epithelial tissues. 
 
Hence, it was hypothesized that supplementation of rHuKGF facilitates the induction 
of a regenerative response in distal lung parenchyma in elastase induced 
emphysematous lungs of mice. The current study was initiated by treating 
emphysematous lungs with 10 mg/kg body weight of rHuKGF at three occasions. 
Substantiation regarding beneficial regenerative response in distal lung parenchyma 
was validated by performing non invasive lung function test and quantitative 
morphometry. Furthermore, on molecular level, candidate genes that are associated 
with biological processes implicated in the repair of alveolar gas exchange area, i.e. 
alveolar epithelium, capillary endothelium and interstitial tissue were also evaluated 
by means of quantitative real time reverse transcriptase-polymerase chain reaction 
(RT-PCR), immunohistochemistry and Western blotting. 
 
In order to assess if the beneficial effects of rHuKGF on the interstitial tissue 
compartment are linked to alveolar epithelial type 2 (AE2) cell-derived transforming 
growth factor β-1 (TGFβ-1), the effect of rHuKGF on mRNA expression levels in and 
release of active TGFβ-1 protein from in-vitro model of primary mouse AE2 cells, 
murine AE2-like cell line LA-4 and AE1-like cell line E10 as well as LA-4/mouse lung 
fibroblast (MLF) co-cultures was studied. The effect of rHuKGF on MLF cells was 
examined in order to evaluate whether rHuKGF directly interact with fibroblast cells to 
affect mRNA expression of TGFβ-1 and its target genes. The importance of TGFβ-
signaling as a potential mediator of the AE2-linked effects of rHuKGF was 
investigated in LA-4/MLF co-cultures in the presence or absence of the neutralizing 
anti-TGFβ antibody 1D11.                            
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3 Materials 
3.1 Animals  
Male C57BL/J mice (Harlan Winkelmann, Hannover, Germany). 
3.2 Antibodies 
Table 1 - 
Antibodies Supplier 




Donkey anti-rat IgG conjugated to fluoresceine 
Isothiocyanate (FITC) 
Goat anti-rabbit conjugated to Texas red 
Goat horseradish peroxidase-linked secondary 
antibody 
Monoclonal mouse anti-PCNA antibody 
Monoclonal rat anti-Mouse Ki-67 antibody 
 
Mouse β-actin antibody 
Polyclonal rabbit anti-TGF-β1 antibody 
Polyclonal rabbit anti-TGF-β2 antibody  
Polyclonal  rabbit anti-VEGFR2 antibody                
R&D System  GmbH Wiesbaden-
Nordenstadt, Germany 
Vector Laboratories, CA, USA 
Vector Laboratories, CA, USA 
Dianova, Hamburg, Germany 
 
Dianova, Hamburg, Germany 
Pierce, Rockford, U.S.A. 
 
DakoCytomation, Denmark  
Dako Deutschland GmbH, Hamburg, 
Germany 
Abcam, Cambridge, UK 
Biozol, Eching, Germany 
Santa Cruz, Burlingham, CA, USA 
Abcam, Cambridge, UK 
 
3.3 Biochemicals and chemicals 
Table 2 -  
Biochemicals and chemicals Supplier 
1% SDS 
100 mM dNTPs 
Biorad Laboratories, Hercules, USA 
    Invitrogen, Karlsruhe, Germany 
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4-15% Tris-HCL Criterion™ pre-cast gel 
3, 3`-diaminobenzidintetrahydrochloride-
(DAB) 
Bio-Rad, Hercules, USA 
Sigma, Steinheim, Germany 
5x Tris-Borate-EDTA  Sigma-Aldrich, Steinheim, Germany 
6x Loading Dye Solution MBI Fermentas, Germany 
Agar-Agar Merck, Darmstadt, Germany 
Agarose NEEO Ultra-Qualitat Roth, Karlsruhe, Germany 
Absolute ethanol Roth, Karlsruhe, Germany 
Alcoholic Eosin  Sigma, Steinheim, Germany 
Beta-Marcaptoethanol (98%)  
CL- X Posure™ film           
Sigma, Steinheim, Germany 
Pierce, Rockford, USA 
DMEM nutrient medium Life Technology, Karlsruhe, Germany 
Ethidiumbromide 
F12K nutrient medium 
Roth, Karlsruhe, Germany 
Gibco, Carlsbad, CA, USA 
Glacial acetic acid Merck, Darmstadt, Germany 
Glycine MP Biomedicals, CA, USA 
KH2PO4 Merck, Darmstadt, Germany 
Mayer’s Hematoxylin Merck, Darmstadt, Germany 
Methanol Roth, Karlsruhe, Germany 
Milk powder Merck, Darmstadt, Germany 
NaCl Roth, Karlsruhe, Germany 
NaHPO4 Sigma, Steinheim, Germany 
Novex® Tris-Glycine SDS sample Invitrogen, Karlsruhe, Germany 
Paraffin   Vogel, Giessen, Germany 
Paraformaldehyde (PFA) Roth, Karlsruhe, Germany  
Phosphate buffered saline (PBS) 
Porcine pancreatic elastase (PPE) 
PVDF transfer membranes 
rHuKGF 
rHu TGFβ-1 
PAA Laboratories, Colbe, Germany 
Roche, Basel, Switzerland 
Life Science Product, Boston, USA 
Amgen, USA 
R&D system, Minneapolis, MN, USA 
Streptomycin PAA Laboratories, Pasching, Austria 
Tris Roth, Karlsruhe, Germany 
Tri-Na-citrate-dihydrate Roth, Karlsruhe, Germany 
Xylene     Merck, Darmstadt, Germany 
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3.4 Buffers and Solutions  
Table 3 -  
Buffer Composition 
10 mM Citrate buffer 
 
Tri-Na-citrate-dihydrate – 29.41 g 
Distilled water – 1000 ml 
The pH was adjusted with HCl to 6 
 





Tris – 60.57 g 
Distilled water – 1500 ml 
The pH was adjusted with HCl to 7.4 
 
Tris--Glycine buffer (10 x) – 2000 ml 
1% SDS – 20 ml 
 
TBS buffer NaCl – 53 g 
Tris – 12 g   
Distilled water – 1000 ml 




Tris glycine buffer (10 x) – 640 ml 
Methanol – 1600 ml 
Distilled water – 5760 ml 
 
2% Agar Agar 
 
Agar-Agar – 2 g 
Tap water – 100 ml 
 
2% Milk solution 
 
Milk powder – 2 g 
PBS – 100 ml 
 
6% PFA solution 
 
Paraformaldehyde – 6 g 
PBS- 100 ml 
 
Alcoholic acetic acid solution 
 
Alcoholic Eosin – 200 ml 





chloride – 0.2 g 
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Tris-HCl buffer – 200 ml 
 
 
3.5 Cell Lines 
Table 4 -  
Cell lines  Supplier 
Mouse lung epithelial cell (LA4) 
 
Mouse  embryonic lung fibroblast 
cell  (MLF) 
American Type Culture Collection, 
Rockville, MD,USA 




Table 5 -  
Enzymes Supplier 
Recombinant RNasin Inhibitor 
Taq DNA Polymerase 
Promega, Madison, USA 
Invitrogen, Karlsruhe, Germany 
 
3.7 Equipment 
Table 6 - 
Equipment Supplier 
A/D converter DT301 PCI, Marlboro, MA 
Amplifier Gould Universal Amplifier, 
Dietzenbach, Germany    
Biofuge Centrifuge  Heraues , Wehrheim, Germany 
Criterion electrophoresis chamber for 
western blotting 
Biorad, Hercules, USA 
Electrophoresis chamber for agarose gel Gentechnology System, Heidelberg, 
Germany 
Gel documentation system Biorad, Hercules, USA 
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Heating-blocks Roth, Karlsruhe, Germany 
iCycler PCR machine Biorad, Hercules, USA 
Microplate autoreader Tecan, Salzburg, Austria 
Notocord hem 3, 5 
Olympus BX 51 
Pneumotechograp 
 
Polyester transwell membranes 
Notocord, Paris, France 
Olympus GmbH, Germany 
PTM 378/1.2 Hugo Sachs Electronic 
March-Hugstetten, Germany 
Fisher Sci. Schwerte, Germany 
Pressure transducer 8T-2, Gaeltec, Dunvegan, Scotland 
RoboCycler® thermocycler Stratagene, USA 
Rotation microtome Leica, Germany 
Stereology Software Package 
UV-spectophotometer 
Olympus, Denmark 
Pharmacia Biotech, Cambridge, UK 
Vortex IKA®, Wilmington, USA 
 
3.8 Fragment Length Standards  
Table 7- 
Fragments length standards Supplier 
100 bp DNA Ladder                                       
Novex® Sharp Pre-stained Protein 
Standards 
Promega, Madison, USA 
Invitrogen, Karlsruhe, Germany 
3.9 Kits  
Table 8 -  
Kits Supplier 
 
Avidin/Biotin Blocking Kit 
BCA™ protein assay Kit 
Vector Laboratories, USA 
Pierce, Rockford, USA 
Chemiluminescence’s detection Kit 
 
Elisa Kit 
SuperSignal® West Femto, Pierce, 
USA 
R&D System  Gmb Wiesbaden-
ordenstadt, Germany 
Ominiscript Reverse Transcriptase Kit Qiagen, Hilden, Germany 
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Rneasy Kit              Qiagen, Hilden, Germany     
SYBR™ Green PCR mix Kit Abgene® Thermo Fischer Scientific, 
UK 
Total Protein Extraction Kit Biochain Institute, Hayward, CA, USA 
Vector M.O.M. (Mouse on mouse) Kit Vector Laboratories, USA 
Vecta Stain Elite ABC Kit   Vector Laboratories, USA 
3.10  Oligodeoxynucleotides  
Oligo (dt) 12-18 Primers were obtained from Invitrogen, Karlsruhe, Germany. Target 
genes primers were obtained from Biomer, Ulm, Germany.  
Table 9 - 




























































































































































3.11  Serum 
Table 10 – 
                   Serum Supplier 
Fetal bovine serum 
 
Normal goat serum 
Gibco-BRL, Eggenstein, Germany 
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4 Methods  
4.1 Experimental design: In-vivo experiments 
4.1.1 Mouse model 
Eleven weeks old C57BL/6 male mice of weight 28.3±1.9 g were included in the 
study. All animal experiments were approved by the regional government 
(Regierungspräsidium Giessen, Dezernat V 54, Giessen, Germany) in accordance 
with the guidelines that complied with national and international regulations. Mice 
were housed in humidity- and temperature-controlled rooms and were allowed food 
and water ad libitum. Experimental mice were distributed into A) treatment groups 
and B) therapy groups as per described below (Fig.4). Instillation of porcine 
pancreatic elastase (PPE), phosphate buffered saline (PBS), and rHuKGF was done 
by oropharyngeal aspiration method as per follow:  
 
Oropharyngeal aspiration: To instill either PPE or rHuKGF (or PBS) into the mice 
lungs, mice were initially anesthetized by isofluran and immediately suspended by 
their upper incisors from a rubber band. The tongue was gently extended out and 
with the help of forceps, the nose was occluded to force the animal to swallow via the 
mouth. Thus, the liquid volume of either PPE or rHuKGF (or PBS) that was placed 
into the distal part of the oropharynx was aspirated into the lungs. 
 
A) Treatment groups- 
PPE group: To induce emphysema by elastase in the mice lungs (n=7), mice were 
initially anesthetized and 2.25mg/kg b.w of PPE, which was dissolved in PBS to 
make a final volume of 80 µl, was instilled by oropharyngeal aspiration method at day 
0 & 10.  
 
PBS group: As a control to PPE-instillation, 80 µl of PBS was instilled directly into the 
lungs of control mice (n=5), at day 0 & 10, by oropharyngeal aspiration as per 
described for the PPE group.  
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B) Therapy groups- 
PPE+KGF group: Emphysema in mice (n=6) was induced as per described in PPE 
group. On day 31, 34, and 37 respectively, PPE treated lungs received 10 mg/kg b.w 
of rHuKGF dissolved in PBS to make a final volume of 80 µl per oropharangeal 
aspiration.  
 
PPE+PBS group: Emphysema in mice (n=6) was induced as per described in PPE 
group. On day 31, 34 and 37 respectively, PPE treated lungs to be used as a 
treatment control received 80 µl of PBS alone per oropharyngeal aspiration.  
.  



















Figure 4 - Schematic representation of experimental design. 
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4.1.2  Lung function analysis by non invasive head-out body 
plethysmography 
Lung function was assessed in each group by head-out body plethysmography (169). 
This method was used to analyse the breathing pattern of each animal by 
continuously registering changes in airflow during inspiration and expiration. Mice 
were positioned in the head-out body plethysmograph with the head protruding 
through a neck collar (9-mm ID, dental latex rubber) attached to an exposure 
chamber. Before starting the monitoring of respiratory function, mice were allowed to 
acclimatize for 15 min in the body plethesmograph.  The airflow was measured with a 
pneumotachograph and a differential pressure transducer coupled to an amplifier. 
These devices were attached to the top port of each plethysmograph chamber. For 
each mouse, the amplified analog signal from the pressure transducer was digitized 
by an analog-to-digital converter at a sampling rate of 2,000/s and the mid-expiratory 
airflow (EF50, i.e. the expiratory airflow when 50% of the tidal volume (VT) is 
exhaled) was calculated by means of the software program in ml/s for each breath 
over a period of 15 minutes. Difference in EF50 values were calculated to the 











Figure 5 - Schematic drawing of the head-out plethysmograph system used for the 
measurement of breathing patterns in mice. 
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4.1.3 Lung fixation   
Mice were euthanized by cervical dislocation on day 31 (PPE- and PBS- group) or on 
day 40 (PPE+KGF- and PPE+PBS- group). Through the tracheotomy, a cuffed endo-
tracheal tube was inserted and securely tied to the trachea. The thoracic cavity was 
opened and the lungs were perfused free of blood with isotonic saline through the 
right ventricle of the heart. The left lung was removed for molecular biology studies 
whereas the right lung was inflated through the trachea with 6% phosphate-buffered 
paraformaldehyde at a pressure of 20 cm of fluid column for 20-25 minutes. The right 
main bronchus was ligated tightly and after submersion in the same fixative, lungs 
were stored in the refrigerator overnight. Lung volume was measured by fluid 
displacement (170). Subsequently, the lungs were embedded into 2% aqueous 
agarose and stored for 2 hour in the cold. According to the principle of systematic 
uniform random sampling (171), embedded lungs were cut into equidistant slices of 
2-mm thickness. 
4.1.4 Lung tissue preparation: Paraffin embedment 
Paraffin embedding is a process in which fixed tissue (utilizing neutral buffered 
formalin or another fixative) is infiltrated by paraffin to harden the tissue and to 
stabilize it for long-term storage and thin sectioning. Agarose embedded lung tissue 
slices were placed into 10% neutral buffered formalin for 1 hour at a temperature of 
40°C. Further, tissue slices were placed in 96% ethanol and incubated at 40°C for 20 
min. This process was repeated two times. Thereafter, tissue slices were transferred 
to 100% ethanol and incubated for 20 min at 40°C. This step was repeated twice by 
transferring the tissue slices to fresh 100% ethanol. Further, tissue slices were 
transferred to xylene and incubated for 60 min at 40°C. This step was repeated one 
more time by transferring the tissue slices to fresh xylene. Afterwards, tissue slices 
were added to the melted paraffin at 60°C. Paraffin was changed three times until the 
tissue slices were infiltrated completely. Subsequently, infiltrated tissue slices were 
placed into a block of molten paraffin and allowed to cool and solidify before making 
tissue sections.  
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4.1.5 Lung tissue sectioning and histochemical staining  
Paraffin blocks were placed into the microtome in a position that top and bottom 
edges were parallel with the blade in order to get even 2 µm thick cuts. With the help 
of small paintbrush, rolling and wrinkling of sections were prevented and sections 
were placed in clean slides. To evaporate the water and to fix the sections on glass, 
all slides were kept in heater at 37°C overnight. In order to proceed with histological 
staining, slides were first de-paraffinized by immersing in xylene for 15 minutes twice 
until the paraffin had been dissolved. Thereafter, slides were hydrated by passing 
them through graded alcoholic solutions, in 100% for 10 min, 96% for 5 min and 70% 
for 10 min. 
 
Hematoxylin is the oxidized product of the logwood tree known as hematein and in 
order to use it as a stain it must be "ripened" or oxidized. Hematoxylin, being a basic 
dye, has an affinity for the basophilic structures containing nucleic acids, such as the 
ribosomes, chromatin-rich cell nucleus, and nucleic acids of the cell nucleus. Eosin is 
fluorescent red acidic dye with an affinity for cytoplasmic components of the cell. 
After hydrogenation, slides were rinsed off in tap water and were immersed in 
Mayer’s Hematoxylin for 5 min and rinsed off in running water to get blue in colour. 
Slides were then stained with alcoholic eosin with glacial acetic acid solution for 5 
min and rinsed off with running water to remove extra staining. In order to 
dehydration, stained slides were taken through a series of alcoholic solution with 
ascending order with 70% alcohol for 10 min, 96% alcohol for 5 min, 100% alcohol 
for 10 min and finally slides were kept in xylene for 10 min and afterwards tissue 
sections were covered with cover-slip to preserve them for long time. 
4.1.6  Quantitative stereological analysis 
Morphometric-based quantification was conducted on H&E-stained slides using a 
BX51 Olympus light microscope linked to a computer assisted stereology toolbox 
(C.A.S.T.). To assess air space enlargement, the mean chord length (MCL), the most 
commonly used indicator of emphysema (172), was quantified by superimposing a 
line grid on the images of lung sections at a magnification of 852.6x. Points on the 
lines of the grid hitting the air spaces and intercepts of the lines with alveolar septa 
were counted to calculate MCL (Fig.6) according to the formula: 
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                                   MCL = Σ Pair x L(p) / (Isepta / 2)   (µm) 
where Σ Pair is the sum of the points of the grid overlaid air spaces, L(p) is the line 
length per point and Isepta is the sum of the intercepts of alveolar septa with the lines 
of the grid. 
 
Morphometric assessment of alveolar surface area per unit volume of lung 
parenchyma (Sv), absolute volume of alveolar air spaces (Vair), absolute volume of 
alveolar septal tissue (Vast) were determined by counting the number of points that 
fell on alveolar septal tissue, alveolar space, other structures such as airways and 
capillary lumen, and by counting the number of intercepts with alveolar septal surface 
at a magnification of 852.6x (Fig.7) according to the following formulas: 
                                   Sv = 2 x Isepta / (Σ Ppar x 78.7/4)   (1/µm) 
                                   Vair = [(Σ Pair) x 16] / (Σ Ppar x Vv (par, lung) x VRL )  (mm³) 
                                   Vast = Σ Past / (Σ Ppar x Vv (par, lung) x VRL)  (mm³) 
where Σ Ppar is the sum of the points of hitting parenchyma, 78.8/4 is the line length 
per test point in µm, Σ Past the sum of points of hitting alveolar septal tissues, and 
Isepta the sum of the intercepts with alveolar septa. 
Vv (par, lung) is the volume of parenchyma per volume of lung and was estimated by 
counting the points that fell on parenchyma relative to points on total lung using 
425.4 x magnification (Fig.8) and calculated as: 
                                   Vv (par,lung) = Σ Ppar / Σ Plung tiss  
VRL is the actual volume of the right lung obtained by the following formula.  
                                   VRL = Vflu disp * Σ Plung / Σ Pall   (mm³) 
where Vflu disp is the volume measured by fluid displacement (175), Σ Plung the test 
point hitting lung cross section and Σ Pall the test points hitting lung and adhering 
tissues.  
 
For correction of global shrinkage of tissues due to processing, area shrinkage was 
measured and correction factors for both linear and volume shrinkage were derived 
using the following formulas: 
                                  Section area = Σ Plung * A (p)   (cm²) 
                                  Expected area = VRL / 0.2945   (cm) 
          Area Shrinkage = (Section area – Expected area) / Expected area 
                                  Linear Shrinkage = Square root of Area Shrinkage 
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                                  Volume Shrinkage = (Linear Shrinkage) ³ 
where A(p) is the area per test point and 0.2945 is the mean thickness of the lung 
slices. Therefore, MCL was corrected for shrinkage by dividing it by the group-mean 
linear shrinkage factor. Total volume of right lung (VRL) and total alveolar surface 
area (Sa, in cm2) were corrected for tissue shrinkage as follows: 
                                   VRL (corrected) = VRL * (1- volume shrinkage) 
                                   Sa = Sv * VRL (corrected)   (cm²) 
 
 In addition, arithmetic mean thickness of the alveolar septal wall (τast) was calculated 
according to the formula:  
                                   τast =  Vast / Sa   (cm) 
 
 
Figure 6 - A lines grid generated by C.A.S.T. was superimposed on each section of 
lung tissue. Points of lines hitting air spaces [(Σ Pair), marked with red triangle] and 
total number of intecepts of the lines with alveolar septal surfaces [(Isepta), marked 
with green circle] were counted to calculate MCL. (This image is a screenshot 
captured on C.A.S.T. to demonstrate the counting procedure)                                   
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Figure 7 - A grid with points and line segments generated by C.A.S.T. was 
superimposed on each section of lung tissue. Points (red crosses) overlying alveolar 
air space [(Σ Pair), marked with red triangle], alveolar septal tissue [(Σ Past) marked 
with green circle] and capillary lumens [(Σ Pcaplu), marked with yellow square] were 
counted to estimate points on parenchyma (Σ Ppar). Additionally, the total number of 
intercepts of the line segments with the alveolar septal surfaces [(Isepta), marked with 
green triangle] were counted. (This image is a screenshot captured on C.A.S.T. to 
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Figure 8 - A grid with points generated by C.A.S.T. was superimposed on each 
section of lung tissue. Points (red crosses) falling on lung parenchyma i.e. alveolar air 
spaces, alveolar septa [(Σ Pparen), marked with red triangle] and non-parenchyma i.e. 
airways, blood vessels [(Σ Pnonparen), marked with green circle] were counted. The 
sum of Σ Pparen and Σ Pnonparen represented Σ Plung and the sum of Σ Pparen, Σ Pnonparen 
and Σ Pnonlung represented points on all embedded tissues (Σ Pall) and were used to 
calculate Vv (par, lung) and VRL. (This image is a screenshot captured on C.A.S.T. to 
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4.1.7  Immunohistochemistry  
4.1.7.1  PCNA immunostaining  
To study the PCNA protein expression in the tissues, immunohistochemistry with 
anti-PCNA antibody was accomplished using a mouse-on-mouse (M.O.M.) peroxide 
kit. Paraffin embedded tissue sections were deparaffinized by immersing in thrice 
changes of xylene for 15 min each and then in absolute alcohol. In order to inhibit 
endogenous peroxidase, sections were blocked with 3% H2O2 in methanol for 30 
min. Thereafter, to recover antigenicity of tissue, antigen retrieval was performed by 
boiling sections in citrate buffer (at 450 W, 1mM, pH 6) for 5 min in a microwave oven 
for three times. Sections were then washed with PBS for 5 min and subsequently 
pre-treated with 100 µl avidin for 15 min, washed with PBS for 5 min followed by 
treatment with biotin solution for 15 min. Thereafter, sections were incubated with 
blocking reagent (M.O.M. Kit) for 1 hour to block non-specific binding of 
immunoglobulin and subjected to washing in 2% milk powder solution for 5 min and 
treated with 100µl M.O.M. diluent for 5 min. Afterwards, sections were incubated with 
mouse anti-PCNA primary anitibody (dilution 1:600 in PBS) for 1 hour at 37°C 
temperature. Once the primary antibody was bound to the antigen of interest, the 
biotinylated anti-mouse IgG secondary antibody was added (dilution 1:100 in PBS) 
for 10 min, forming a biotinylated antibody complex bound to the target antigen. 
Thereafter, sections were exposed to avidin-biotin-conjugated peroxidase for 30 min 
at room temperature and to diaminobenzidine tetrahydrochloride (DAB) for 10 min 
which resulted in brown staining. After rinsing in water, counterstaining was 
performed with Mayer's hematoxylin solution and sections were dehydrate through 
70% alcohol for 10 min, 96% alcohol for 5 min and absolute alcohol for 10 min and 
kept in xylene for 15 min.  
 
4.1.7.2 TGF-β1 immunostaining  
TGFβ-1 immunostaining was done using avidin-biotin-complex (ABC) technique. 
Paraffin embedded sections were deparaffinised and rehydrated followed by blocking 
in 3% H2O2 in methanol as described above. After antigen retrieval and washing in 
TBS for 5 min, sections were blocked with 10% normal goat serum (dilution 1:10 in 
PBS) and incubated with polyclonal rabbit anti-TGFβ-1 primary antibody (dilution 
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1:100 in PBS) for 1 hour at 37°C and sequentially subjected to biotinylated anti-rabbit 
secondary antibody (dilution 1:100 in PBS) for 30 min. After washing sections with 
PBS for 5 min, signels were visualzed using avidin-biotin-conjugated peroxidase for 
30 minutes and diaminobenzidine tetrahydrochloride (DAB) for 10 min. Thereafter, 
sections were rinsed in water, counterstained with Mayer's hematoxylin solution and 
dehydrated through 70% alcohol for 10 min, 96% alcohol for 5 min and absolute 
alcohol for 10 min and kept in xylene for 15 min.  
. 
4.1.7.3 TGF-β2 immunostaining  
TGFβ-2 immunostaining was performed using avidin-biotin-complex (ABC) 
technique. Dewaxed paraffin sections were blocked with 0, 9% H2O2 in methanol as 
described above. After washing, the slides were incubated with normal goat serum 
(dilution 1:10 in PBS) for 20 min. The slides were then incubated with polyclonal 
rabbit anti-TGF-β2 primary antibody (dilution 1:50 in PBS) for 1 hour at 37°C, rinsed 
and subsequently incubated with biotinylated anti-rabbit secondary antibody (dilution 
1:100 in PBS) for 30 min. After washing in PBS, signals were visualized using avidin-
biotin peroxidase with diaminobenzidine tetrahydrochloride (DAB) for 10 min and 
counterstained with Mayer’s hematoxylin solution. Unless stated otherwise, all steps 
were performed at room temperature.  
 
4.1.8 Double immunofluorescence microscopy 
In order to perform double immunofluorescence staining, dewaxed and microwave 
pre-treated paraffin sections of lung were incubated with monoclonal rat anti-mouse 
Ki-67 (clone TEC-3; dilution 1:3 in PBS) which is a marker of proliferating cells (191), 
and polyclonal rabbit antipodocalyxin (kind gift from Dr. M. Farquhar, La Jolla, CA; 
dilution 1:1000 in PBS) which is a marker of endothelial cells (192), for 1 hour at 
room temperature followed by specific donkey anti-rat IgG conjugated to fluoresceine 
isothiocyanate (FITC, dilution 1:200 in PBS), and goat anti-rabbit IgG conjugated to 
Texas Red (dilution 1:100 in PBS) for 1 hour at room temperature. 
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4.2 In-vitro experiments 
To have a better understanding if the effects of rHuKGF on interstitial tissue 
compartment observed in-vivo were mediated via alveolar epithelial type 2 (AE2) 
cells derived TGFβ-1, an in-vitro model of primary AE2 cells isolated from C57BL/6 
mouse lungs, murine cell line LA-4 which exhibits an AE2-like phenotype (173) and   
E10 which exhibits an alveolar epithelial type 1 (AE1)-like phenotype (174), as well 
as of murine embryonic lung fibroblast cell line MLF and LA-4/MLF co-cultures were 
utilized as described below. 
4.2.1 Isolation of primary lung alveolar epithelial type 2 (AE2) cells 
Mouse primary AE2 cells (which were kindly provided by Prof. Bernd Müller, Philipps-
University, Marburg) were isolated from C57BL/6 mice using a slightly modified 
protocol described previously (175). Briefly, mice were anaesthetized by 
intraperitoneal injection of pentobarbital sodium (50 mg/kg b.w.) mixed with 100 IU 
heparin sodium. As soon as deep anaesthesia was achieved, thoracotomy was 
performed and the trachea was cannulated.  An incision was made in the vena cava 
and the lungs were perfused free of blood via the pulmonary artery and removed 
from the thorax. Lungs were instilled with 650 U of PPE. Digestion with elastase was 
allowed to take place at 37°C for 20 min before the large airways were removed. In 
the presence of DNAse I (250 µg/ml), the lungs were minced with scissors and the 
elastase reaction was then stopped by addition of 5 ml fetal bovine serum per lung. 
The final cell suspension was filtered several times through gauze nylon and washed 
by gentle centrifugation. The cell pellet was resuspended in DMEM cell culture 
medium and transferred to mice immunoglobulin G-coated bacteriological Petri 
dishes to a density of 30x106 cells. After incubation for 1 hour at 37°C in a 10% CO2-
air incubator, alveolar macrophages were adherent to the plastic dishes whereas 
AE2 cells were unattached and could therefore, be removed, centrifuged, and used 
for subsequent cell culture experiments. The purity of the cell preparation was 
evaluated by means of Papanicolaou staining to be greater than 95%. Finally, the 
primary AE2 cells were cultured in 12-well plates at concentrations of 1x105 cells/well 
using DMEM cell culture medium. After 24 hours, cells received fresh medium 
supplemented with 50 ng rHuKGF per ml or an equivalent amount of PBS as a 
control. After 6 hours and 24 hours cells were harvested using RLT buffer for real 
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time RT-PCR analysis of gene expression and cell culture supernatants were 
collected for measurement of activated TGFβ-1 concentrations by standard ELISA 
procedures as described below. 
4.2.2 Cell culture conditions 
Cells of the mouse lung epithelial cell lines LA-4, E10 and MLF were cultured in F12K 
nutrient mixture supplemented with 10% fetal calf serum, 1% glutamine, 10.000 U/mL 
penicillin, and 10.000 µg/mL streptomycin. The murine lung epithelial cell line E10 
was kindly provided by M. Williams (Pulmonary Center, Boston University School of 
Medicine, Boston, MA, USA). This cell line was generated by A. Malkinson (Denver, 
CA) and has an AE1 cell like phenotype e.g. expression of caveolin-1, aquaporin-5, 
T1α and other AE1 cell−related proteins (174). 
Cells were seeded into 12-well plates at concentrations of 1x105 cells/well. After 2 
days in culture, cells had reached 80% confluency, and culture medium was 
changed. Cells received fresh medium supplemented with either 50 ng rHuKGF per 
ml, 10 ng recombinant human TGFβ-1 (rHuTGFβ-1) per ml or an equivalent amount 
of PBS as a control. After treatment for 6 hours and 24 hours cell culture 
supernatants were collected for measurement of activated TGFβ-1 concentrations by 
standard ELISA procedures as described below or cells were harvested using RLT 
buffer for real time RT-PCR analysis of gene expression. 
4.2.3 Co-culture of epithelial (LA-4) and fibroblast (MLF) cells 
LA-4 were seeded onto Polyester Transwell membranes (Costar, insert membranes 
with pore size 0.4 µm) at concentrations of 1x105 cells/well and incubated for 8 
hours. F12K nutrient cell culture medium, supplemented with 10% FCS, 1% 
glutamine, 10.000 U/mL penicillin, and 10.000 µg/mL streptomycin was changed, and 
1x105 MLF cells were placed into the 12-well Costar Transwell plates. After 
incubation for 48 hours, cells received fresh medium supplemented with 50 ng 
rHuKGF per ml or an equivalent amount of PBS as a control. Co-cultures were 
incubated with rHuKGF or PBS in the presence or absence of anti-TGFβ neutralizing 
antibody (clone 1D11, 20 µg/ml) or control IgG1. Clone 1D11 neutralizes the activity 
of TGFβ-1, -2, and -3. Cell supernatants were collected for measurement of activated 
TGFβ-1 concentrations by standard ELISA procedures as described below. 
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4.3 RNA isolation, RNA quantity, and purity measurement 
Thirty milligram frozen lung tissues were chopped off with sterile scalpel. Chopped off 
pieces were collected in 1.5ml sterile eppendorf tubes. Fine chopped tissue pieces 
were immersed in 800µl of RLT buffer with 8µl beta-mercaptoethanol. Tissue 
homogenate was prepared using a sterile needle and syringe until a fine tissue 
mixture was obtained. Immediately afterwards, total cellular RNA was isolated using 
Qiagen’s RNeasy column technology method as per the instructions given for the 
Qiagen RNeasy Miniprep kit.  
 
Total RNA quantification and purity was determined with an Ultraspec 2100-
spectrophotometer. The quantity of the isolated RNA was calculated from the 
absorbance at 260 nm, and the purity was determined by calculating the ratio at 
optical density260 nm/optical density280 nm.  
4.4 cDNA synthesis 
First-strand cDNA was synthesized by introducing equal amounts of RNA (2.0µg) 
from each sample in a total reaction volume of 20 µl using an Omniscript RT kit by 
adding 1µl RNasin inhibitor, 2µl oligo dTs primers, 2µl 10X RT buffer, 2µl 5mM dNTP, 
1µl reverse transcriptase. Total reaction volume of 20µl was adjusted with RNase 
free water. Reverse transcription reactions were performed for 1 hour at 37°C and 5 
min at 93°C. 
4.5 Quantitative real-time PCR 
To determine the relative mRNA expression of target genes (see table 9), real-time 
PCR was performed in 96-well format iCycler Detection System from BioRad system. 
Each 20 µl reaction mixture contained 10 µl of SYBR Green PCR mix, 1 µl of each 
gene-specific forward and reverse primer (10 pmol/ µl), 1 µl cDNA, and 7 µl water. 
The thermal cycle conditions used for all reactions were as follows: 95°C, 15 min; 
95°C, 50 sec; sequence-specific primer’s annealing temperature, 40 sec; 72°C, 
40 sec; 72°C, 5 min. Amplification curves were evaluated using the instrument’s 
software according to the analysis standards given in the manual. The crossing point 
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data [Cycle threshold (Ct) values] were exported to spread sheet software (MS-
Excel) for further analysis. 
 
The relative mRNA expression of the target genes were normalized with the 
endogenous reference gene glyceraldehydes 3-phosphate dehydrogenase (GAPDH) 
using the formula 2 raised to the power of delta cycle threshold (2∆Ct), where ∆Ct = 
Ct, reference gene – Ct, target gene. Differences between groups were calculated 
with respect to controls (1%). 
4.6 Protein extraction and quantification 
Protein was extracted from 100 g lung tissue using total protein extraction kit from 
Biochain according to the manufacturer's protocol. The protein concentration of each 
sample from lung tissues was determined using a BCA™ protein assay kit according 
to their respective protocol.  
 
To quantified β-actin, PCNA and VEGFR2 expressions, 25 µg of protein from each 
sample was mixed with Tris-Glycine SDS sample buffer and were fragmented by 
adding 5 µl of β-mercaptoethanol followed by heating for 5 min at 95°C. Proteins 
were subjected to electrophorosis on 4-15% Tris-HCL Criterion™ pre-cast gel at 60 V 
for 30 min and 120 V for 90 min and blotted to PVDF transfer membrane. Novex® 
sharp pre-stained protein standard was used as standard in SDS-PAGE. Non-
specific sites on blots were blocked with 10% skim milk in PBS for 1 hour. Blocked 
blots were incubated with primary antibodies against β-actin, PCNA and VEGFR2 for 
overnight at 4°C. Blots were washed with PBS twice for 10 min and then incubated 
with horseradish peroxidase–linked secondary antibody (1:400) for 1 hour at room 
temperature. Blots were washed again with PBS twice for 10 min; specific bands 
were visualized by autoradiography using enhanced chemiluminescence according 
to the manufacturer's instructions. Blots were scanned and quantified using computer 
based densitometer and analysis software, which was carried out on negative 
images of the western blots. Expressions of PCNA and VEGFR2 were normalized 
with β-actin expression.  
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4.7 Enzyme Linked Immunosorbent Assay (ELISA) 
Levels of active TGFβ-1 in cell culture supernatants were determined using 
Quantikine ELISA kit according to the manufacturer's instructions. Plates were read 
in a microplate autoreader at 405 nm. A standard curve was generated using the 
known amounts of purified recombinant TGFβ-1 provided with the kit. 
4.8 Statistical analysis 
All data are presented as mean ± SD. Differences between PBS- versus PPE- group, 
and PPE+PBS versus PPE+KGF, were analyzed by t-test if normality and equal 
variance were given (P>0.1). Otherwise the nonparametric Mann-Whitney U-test was 
used. All analyses were performed by using GraphPad Prizm 4 software program (EI, 
Camino Rea, San Diego, CA, USA). Values of P<0.05 were considered to be 
significant. 
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5 Results  
5.1 Effects of rHuKGF in in-vivo animal model 
5.1.1  Body weight and lung volume 
The body weights of mice from 4 different experimental groups were examined at day 
0, 31 or 40, respectively. No significant differences were observed between day 0 
and day 31 or 40, respectively (Fig.9A). The volume of the right lung (VRL) was 
significantly increased at day 31 in elastase treated lungs compared with PBS treated 
lungs. However, no difference was observed between elastase treated lungs which 






























Figure 9 - Body weight and volume of right lung (VRL) measurements. (A)  Body 
weight of each mouse was measured at two different time points i.e. day 0, 31 or 40. 
No significant difference was obtained on comparison of day 0 with 31 (or 40). (B) 
Mice lungs treated with elastase showed a significant increase in right lung volume 
compared to PBS treated mice. Elastase treated mice lungs receiving rHuKGF 
versus PBS did not show significant changes in lung volume. **P<0.05 versus the 
respective control group. 
5.1.2  Lung function analysis  
To evaluate the influence of rHuKGF on airflow limitation, measurement of mid-
expiratory airflow (EF50) were performed on day 31 for elastase treated lungs versus 
PBS, and on day 40 for elastase treated lungs which had received rHuKGF versus 
PBS. With respect to the lungs treated with PBS (set to 100%), lungs treated with 
elastase showed a significant decline of the EF50 values to 66%. Interestingly, 
rHuKGF significantly reversed the EF50 values to 98% in elastase treated lungs in 



























Figure 10 - Lung function analysis. Mid expiratory airflow (EF50) values were 
reduced in lungs treated with elastase (66%) as compared to PBS treated lungs 
(100%). rHuKGF significantly reversed the impairment of respiratory function (98%) 
in elastase treated lungs in comparison with PBS received elastase treated lungs. 
**P<0.05 versus the respective control group. 
5.1.3 Quantitative stereological analysis   
5.1.3.1 Air space enlargement 
The destruction of alveolar wall leading to airspace enlargement and loss of alveolar 
surface area are classic characteristics of emphysema. To characterise airspace 
enlargement, mean chord length (MCL), absolute volume of air spaces (Vair) and 
alveolar surface area per unit volume (Sv) were quantified (Fig.11). The elastase 
treated lungs showed a significant increase in mean chord length (Fig.11A), absolute 
volume of air spaces (Fig.11B), and a significant reduction in alveolar surface area 
per unit volume (Fig.11C) reflecting marked airspace enlargement in comparison with 
the PBS treated lungs. Interestingly, supplementation of rHuKGF in elastase treated 
lungs resulted in a significant reduction in mean chord length (Fig.11A) and a 
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significant increase in alveolar surface area per unit volume (Fig.11C) in comparison 
with elastase treated lungs which had received PBS. However no significant 
difference was noticed for absolute volume of air spaces between elastase treated 















Figure 11 - Quantitative Morphology. A) Mean chord length (MCL). B) Absolute 
volume of air spaces (Vair). C) Alveolar surface area per unit volume (Sv). MCL and 
Vair were found to be significantly increased whereas Sv was significantly reduced in 
elastase treated lungs in comparison with PBS treated lungs. Further, elastase 
treated lungs which had received rHuKGF showed a significant reduction in MCL and 
a significant increase in Sv compared with elastase treated lungs which had received 
PBS whereas no marked difference was observed in Vair. **P<0.05 versus the 
respective control group.  
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5.1.3.2  Loss of alveolar septa 
Loss of alveolar septa was depicted in elastase treated lungs by a significant 
reduction in alveolar surface area (Sa) when compared to PBS treated lungs 
(Fig.12B). No marked change was observed for absolute volume of alveolar septal 
tissue (Vast) (Fig.12A). In addition, arithmetic mean thickness of the alveolar septal 
wall (τast) was observed to be significantly increased in elastase treated lungs as 
compared to PBS treated lungs (Fig.12C). Elastase treated lungs receiving rHuKGF 
exhibited a significant increase in absolute volume of alveolar septal tissue (Fig.12A), 
alveolar surface area (Fig.12B) and arithmetic mean thickness of alveolar septal walll 

















Figure 12 - Quantitative Morphology. A) Absolute volume of septal tissue (Vast). B) 
Alveolar surface area (Sa). C) Arithmetic mean thickness of alveolar septal wall (τast). 
Vast showed no differences in elastase treated lungs in comparison with PBS treated 
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lungs whereas Sa was significantly reduced and τast was found to be significantly 
increased in elastase treated lungs in comparison with PBS treated lungs. Further, 
elastase treated lungs receiving rHuKGF showed a significant increase in Vast, Sa and 
τast compared with elastase treated lungs receiving PBS. **P<0.05 versus the 
respective control group. 
5.1.4  Lung compartments affected by rHuKGF 
5.1.4.1 Alveolar epithelium  
Proliferative cell nuclear antigen (PCNA), a marker for proliferating cells, is a major 
component of the DNA repair pathway (176-177). To evaluate the proliferative effects 
of rHuKGF on epithelium in elastase induced lung emphysema, 
immunohistochemical analysis for PCNA was performed. rHuKGF therapy resulted in 
a considerable increase in PCNA positive alveolar and airway epithelial cells in 
emphysematous lungs that had received rHuKGF (Fig.13D) while a very rare PCNA 
positive cell was detected in emphysematous lungs that had received PBS (Fig.13C). 
However, in emphysematous lungs, PCNA stained positive cells were very poorly 
observed (Fig.13B) when compared to PBS treated lungs (Fig.13A). 
  




Figure 13 - Immunohistochemical staining for PCNA in paraffin sections of lung 
tissue. rHuKGF aspiration in emphysematous lungs resulted in abundant PCNA 
positive alveolar (shown by arrows) and airway epithelial cells (shown by thick 
arrowheads) as well as alveolar macrophages (AM) (D) compared with 
emphysematous lungs receiving PBS (C). In contrast, PCNA positive cells were very 
poorly seen in emphysematous lungs (B) compared to PBS treated lungs (A). Scale 
bar = 40 µm.  
Furthermore, supplementation of rHuKGF in emphysematous lungs resulted in a 
significant induction of PCNA mRNA expression in comparison with emphysematous 
lungs receiving PBS (Fig.14A).  
 
In addition, mRNA expression of Cyclin-D1, which is an important regulator of cell 
cycle progression and considered to be in association with PCNA (178), was 
significantly induced in emphysematous lungs receiving rHuKGF as compared to 
PBS treated emphysematous lungs (Fig.14B). 
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Likewise, mRNA expression of nuclear factor erythroid-related factor 2 (Nrf2), which 
is a basic leucine zipper transcription factor involved in wound healing and being 
necessary for the appropriate proliferation of alveolar epithelial cells (179), was 
significantly increased after therapy with rHuKGF in emphysematous lungs as 
compared with PBS treated emphysematous lungs (Fig.14C). No significant 


















Figure 14 - rHuKGF therapy was associated with increased expression of marker 
genes of epithelial cell proliferation in vivo. Quantitative real time RT-PCR 
demonstrated significantly increased mRNA levels of PCNA (A), Cyclin-D1 (B) and 
Nrf2 (C) in emphysematous lungs receiving rHuKGF in comparison with 
emphysematous lungs which had received PBS. No significant changes were seen in 
any of the genes between elastase versus PBS treated lungs. **P<0.05 versus the 
respective control group. 
 Interestingly, in line with the RT-PCR data, Western blot analysis revealed that the 
expression of PCNA was significantly higher in emphysematous lungs which were 
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supplemented with rHuKGF as compared with emphysematous lungs receiving PBS. 
No significant difference in the protein levels was found between lungs treated with 


















Figure 15 - Western blot analysis. Protein expression of β-actin (A-I and A-III) and 
PCNA (A-II and A-IV) were detected by Western blotting. Densitometry based 
expression of PCNA normalised to β-actin revealed that PCNA protein expression 
was markedly higher in emphysematous lungs supplemented with rHuKGF as 
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compared with emphysematous lungs receiving PBS. No difference was observed in 
elastase versus PBS treated lungs (B). **P<0.05 versus the respective control group. 
Furthermore, the influence of rHuKGF on differentiation of alveolar epithelial (AE) 
cells was investigated at the mRNA level by looking at the AE type 2 cell (AE2) 
specific marker surfactant protein-C (SP-C) (180-181) and the AE type 1 cell (AE1) 
specific marker aquaporin (AQP)-5 (182) (Fig.16). The mRNA levels of SP-C 
(Fig.16A) and AQP-5 (Fig.16B) were significantly increased in emphysematous 
lungs supplemented with rHuKGF compared with emphysematous lungs receiving 
PBS. Moreover, mRNA levels of forkhead transcription factor (Foxa-2), which has 
been shown to regulate the differentiation of alveolar epithelial cells (183-184), was 
found to be significantly induced in emphysematous lungs supplemented with 
rHuKGF compared with emphysematous lungs receiving PBS (Fig.16C). In contrast, 
a marked reduction in AQP5 and Foxa-2 mRNA levels was observed in 
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Figure 16 - rHuKGF therapy resulted in increased expression of marker genes of 
alveolar epithelial cell differentiaion in vivo. Quantitative real time RT-PCR 
demonstrated significantly increased mRNA expression levels of SP-C (A), AQP-5 
(B) and Foxa-2 (C) in emphysematous lungs receiving rHuKGF therapy compared to 
supplementation with PBS. On other hand, SP-C mRNA levels remained uneffective 
between PBS and emphysematous lungs whereas a significant reduction in mRNA 
levels of AQP-5 and Foxa-2 was observed in elastase treated in comparison with 
PBS treated lungs. **P<0.05 versus the respective control group. 
In addition, mRNA expression of HGF, which stimulates DNA synthesis of airway 
epithelial cells (165) and AE2 cells that contribute to regenerating the alveolar 
structure (164), was significantly increased in rHuKGF administered emphysematous 
lungs as compared with emphysematous lungs receiving PBS (Fig.17A). 
 
Besides, fibroblast growth factor (FGF-7) mRNA level was markedly induced in 







Figure 17 - rHuKGF therapy resulted in increased expression of HGF and FGF-7. 
Quantitative real time RT-PCR revealed that aspiration of rHuKGF in 
emphysematous lungs resulted in a marked induction in mRNA levels of HGF (A) 
and FGF-7 (B) versus emphysematous lungs receiving PBS. No significant changes 
were seen in any of the genes between elastase versus PBS treated lungs. **P<0.05 
versus the respective control group. 
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5.1.4.2  Capillary endothelium 
Capillary endothelial cells are one of the major cell types constituting the alveolar 
septal wall. To determine whether rHuKGF therapy in emphysematous lungs could 
effect on proliferation of capillary endothelial cells, double immunohistochemistry for 
marker for endothelial cells and Ki-67 (which is a cellular marker associated with cell 
proliferation and defines the proliferation status of capillary endothelial cells) was 
performed which revealed that rHuKGF resulted in proliferation of capillary 
endothelium cells (Fig.18A-C) while no Ki-67 stained cell was noted in PBS treated 











Figure 18 - Double immunohistochemical staining for the proliferation marker Ki-67 
(green fluorescence) and podocalyxin, a marker for endothelial cells (red 
fluorescence). rHuKGF administration in emphysematous lungs induced proliferation 
of capillary endothelium cells (A-C) whereas in PBS treated emphysematous lungs 
colocalization of Ki-67 and podocalyxin was not observed (D-F). 
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In addition, therapeutic application of rHuKGF caused a significant increase in mRNA 
expression of vascular endothelial growth factor (VEGF), which is crucial for capillary 
endothlial cells maintenance (82), in emphysematous lungs in comparision with 
emphysematous lungs receiving PBS (Fig.19A). 
The mRNA expression levels of VEGF specific receptors, VEGFR1 and VEGFR2 
were significantly induced in emphysematous lungs which had received rHuKGF when 
compared to emphysematous lungs which had received PBS (Fig.19B-C). 
On the other hand, transcript levels of VEGF and VEGFR2 were found to be 
significantly reduced in emphysematous lungs as compared to control lungs (Fig.19A, 













Figure 19 - rHuKGF therapy was associated with increased expression of genes 
implicated in capillary endothelium maintenance in vivo. Quantitative real time RT-
PCR revealed significantly increased mRNA levels of VEGF (A), VEGFR1 (B) and 
VEGFR2 (C) in rHuKGF supplemented emphysematous lungs when compared to 
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saline treated emphysematous lungs. Elastase treatment alone resulted in reduction 
of VEGF and VEGFR2 mRNA expression as compared to controls (A and C). 
**P<0.05 versus the respective control group. 
To confirm and validate the RT-PCR analysis, Western blot analysis for VEGFR2 
was performed. Likewise, a significantly increased expression of VEGFR2 was 
detected in emphysematous lungs receiving rHuKGF therapy as compared to 
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Figure 20 - Western blot analysis. Protein expression of β-actin (A-I) and VEGFR2 
(A-II) were detected by Western blotting. Densitometry based expression of VEGFR2 
normalised to β-actin revealed that VEGFR2 protein expression was markedly 
induced in rHuKGF supplemented emphysematous lungs versus emphysematous 
lungs which had received PBS. A marked reduction was noticed in emphysematous 
lungs versus PBS treated lungs (B). **P<0.05 versus the respective control group. 
5.1.4.3 Interstitial tissue    
To assess whether rHuKGF influences interstitial tissue maintenance in elastase 
induced emphysematous lungs, immunohistochemical detection of transforming 
growth factorβ-1 (TGFβ-1), a prototypic fibrogenic cytokine which stabilizes interstitial 
tissue formation (185), was performed. Immunohistochemistry revealed an 
enhancement of TGFβ-1 positive alveolar and airway epithelial cells in rHuKGF 
supplemented emphysematous lungs (Fig.21D) in comparison with emphysematous 
lungs receiving PBS (Fig.21C). Emphysematous lungs exhibited a marked reduction 
in TGFβ-1 positive epithelial cells (Fig.21B) when compared with PBS treated lungs 
(Fig.21A). 
 




Figure 21 - Immunohistochemical staining for TGFβ-1 in paraffin section of lung 
tissue. rHuKGF therapy resulted in a marked increase in TGFβ-1 positive alveolar 
(shown by arrows) and airways epithelial cells (shown by thick arrowheads) as well 
as alveolar macrophages in  emphysematous lungs (D) in comparision with 
emphysematous lungs which had received PBS (C). Lungs treated with elastase 
showed only very few TGFβ-1 positive epithelial cells and alveolar macrophages (B) 
compared to PBS treated lungs (A). Scale bar = 40 µm. 
Moreover, TGFβ-1 is implicated to increase the expression of multiple matrix genes 
including elastin, involving TGFβ transmembrane receptor (type 1 and 2) and specific 
smads (153).  
Elastin is a major constituent of alveolar interstitial tissue and its synthesis is an 
essential step in alveolar growth and regeneration (150). To evaluate the effects of 
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rHuKGF on regulators of interstitial tissue formation, mRNA levels of TGFβ-1, TGFβ-
R-1, TGFβ-R-2, Smad 2 and elastin were examined. The mRNA levels of TGFβ-1, 
TGFβ-R-1, TGFβ-R-2, Smad 2, and elastin were found to be significantly induced 
emphysematous lungs receiving rHuKGF compared with emphysematous lungs 
receiving PBS (Fig.22A-D, Fig.24B). In contrast, mRNA levels of TGFβ-1, Smad 2, 
and elastin were significantly reduced in elastase versus PBS treated lungs (Fig.22 
















Figure 22 - rHuKGF therapy resulted in increased expression of genes implicated in 
interstitial cell maintenance in vivo. Quantitative real time RT-PCR revealed 
significantly increased mRNA levels of TGFβ-1 (A), TGFβ-R-1 (B), Smad 2 (C), 
elastin (D) in emphysematous lungs receiving rHuKGF therapy as compared with 
emphysematous lungs which had received PBS. A marked reduction in relative 
mRNA levels of TGFβ-1, Smad 2, and elastin was observed in elastase versus PBS 
treated lungs. **P<0.05 versus the respective control group. 
                                                                                      
 64 
In addition, aspiration of rHuKGF in emphysematous lungs resulted in significantly 
induced mRNA expression levels of plasminogen activator inhibitor (PAI)-1, which is 
regulated by TGFβ and plays a key role to decline the proteolysis of interstitial tissue 
constitutes (186-187), and of zinc finger transcription factor (SP-1) which regulates 
TGFβ-1 transcription (188) as compared to emphysematous lungs instilled with PBS 
(Fig.23A-B). Elastase treatment alone resulted in a significant reduction of SP-1 











Figure 23 - rHuKGF therapy resulted in increased expression of PAI-1 and SP-1 in 
vivo. Quantitative real time RT-PCR revealed that aspiration of rHuKGF in 
emphysematous lungs resulted in a marked induction in mRNA levels of PAI-1 (A) 
and SP-1 (B) versus emphysematous lung which had received PBS. A marked 
reduction in relative mRNA level of SP-1 was observed in emphysematous lungs 
versus control lungs (B). **P<0.05 versus the respective control group. 
In addition, administration of rHuKGF was associated with significantly increased 
mRNA expression of TGFβ-2 in emphysematous lungs in comparison with saline 
treated emphysematous lungs (Fig.24A). In contrast, emphysematous lungs showed a 
significant reduction in mRNA expression of TGFβ-2 as compared with control lungs 
(Fig.24A). 
At the protein level, TGFβ-2 expression was assessed by indirect imunohistochemistry 
in rHuKGF treated emphysematous lungs as compared emphysematous lungs 
receiving PBS. TGFβ-2 positive cells were more frequently detected in rHuKGF 
administered emphysematous lungs where TGFβ-2 was localized to the tips of short 
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side-branches of alveolar septal walls (Fig.24D) while saline treated emphysematous 




























Figure 24 - rHuKGF therapy was associated with increased expression of TGFβ-2 
and TGFβ-R-II in vivo. Quantitative real time RT-PCR demonstrated a significant 
upregulation of relative mRNA levels of TGFβ-2 (A) and TGFβ-R-II (B) in 
emphysematous lungs receiving rHuKGF therapy when compared to saline treated 
emphysematous lung. In emphysematous lungs, a significant reduction in the 
expression of TGFβ-2 (A) was seen as compared to controls. Indirect 
immunohistochemistry revealed that expression of TGFβ-2 was localised in the tips 
of short side-branches of alveolar septal walls (shown by arrows) in emphysematous 
lungs receiving rHuKGF therapy as detected by immunohistochemistry (D). **P<0.05 
versus the respective control group. 
Likewise, in emphysematous lungs receiving rHuKGF, PDGF-A mRNA expression, 
which has been suggested to be required for alveolar septal elastic fiber formation in 
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mice (167), was significantly increased as compared to emphysematous lungs 
receiving saline (Fig.25). Moreover, there was significantly reduced mRNA 
expression of PDGF-A in the lungs with emphysematous changes as compared to 













Figure 25 - rHuKGF therapy resulted in increased expression of PDGF-A in vivo. 
Quantitative real time RT-PCR demonstrated significantly increased mRNA level of 
PDGF-A in rHuKGF administered emphysematous lungs when compared to saline 
treated emphysematous lungs. In emphysematous lungs, significant reduction in the 
expression of PDGF-A was seen as compared to controls. **P<0.05 versus the 
respective control group. 
5.2 Effects of rHuKGF in in-vitro cell culture: 
5.2.1 TGFβ-1 mRNA expression in and release of active TGFβ-1 of 
alveolar epithelial type 2 (AE2) cells. 
In order to investigate if the regenerative effects of rHuKGF on interstitial tissue 
compartment observed in vivo, were caused by AE2 cells derived TGFβ-1, mouse 
primary lung AE2 cells, murine AE2-like cells LA-4 and AE1-like cells E10 were 
incubated with 50 ng/ml of rHuKGF for 6 hours and 24 hours, respectively. Incubation 
with rHuKGF resulted in significantly increased transcript levels of TGFβ-1 in primary 
AE2 cells after 24 hours and in LA-4 cells after 6 hours versus control, whereas E10 
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cells failed to respond (Fig.26A-C). In addition, release of active TGFβ-1 into the 
supernatant was significantly increased above control levels after 24 hours of 
incubation with rHuKGF in primary AE2 cells, in LA-4 cells, and after 6 as well as 24 
hours of incubation with rHuKGF in LA-4 cells co-cultured with mouse lung fibroblast 






















Figure 26 - rHuKGF increased mRNA expression of TGF β-1 in primary AE2 cells 
and murine AE2-like LA-4 cells but not in murine AE1-like E10 cells in vitro.  
Quantitative real time RT-PCR revealed that incubation with rHuKGF significantly 
increased mRNA expression of TGF β-1 in mouse primary AE2 cells, which were 
isolated from C57BL/6 mice, after 24 hours (A), in LA-4 after 6 hours (B), but not in 
E10 cells (C) as compared to controls. **P<0.05 versus the respective control group 













Figure 27 - rHuKGF increased the release of active TGF β-1 in primary AE2 cells, 
murine AE2-like LA-4 cells, and LA4 cells cocultured with mouse lung fibroblast 
(MLF) cells in vitro. Incubation with rHuKGF significantly increased concentrations of 
activated TGF β-1 above control levels after 24 hours in primary AE2 cells (A), in LA-
4 (B), and LA-4/MLF co-cultures after 6 as well as after 24 hours (C). **P<0.05 
versus the respective control group. 
5.2.2 TGFβ-1 increased mRNA expression of genes characteristic of 
the TGFβ-1 pathway in murine fibroblasts. 
In order to evaluate if the effects of rHuKGF on increased expression of elastin, were 
the result of a direct interaction with fibroblasts, MLF cells were incubated with 50 
ng/ml of rHuKGF or 10 ng/ml of recombinant human TGFβ-1 for 6 and 24 hours, 
respectively. Incubation of MLF cells with TGF β-1 resulted in the significant induction 
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of mRNA expression levels of SP1, TGF β-1, PAI-1, and elastin at both time-points, 
while incubation with rHuKGF did not alter the mRNA expression level of any of the 






Figure 28 - rHuKGF does not directly interact with fibroblasts to affect the mRNA 
expression of TGFβ-1 and its target genes. Quantitative real time RT-PCR revealed 
that incubation of mouse lung fibroblast (MLF) cells with TGFβ-1 (10 ng/ml) 
significantly increased mRNA expression levels of TGFβ-1 (A), SP-1 (B), PAI-1 (C) 
and elastin (D) after 6 and 24 hours in comparison with controls, whereas no effect 
was observed in cells incubated with rHuKGF (50 ng/ml). **P<0.05 versus the 
respective control group. 
5.2.3 Effects of neutralization of TGFβ in rHuKGF treated 
epithelial/fibroblast co-cultures. 
To assess if the regenerative effects of rHuKGF on alveolar interstitial tissue 
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LA-4/MLF co-cultures were incubated with or without 50 ng/ml of rHuKGF in the 
presence of neutralizing anti-TGFβ antibody (clone 1D11; 20µg/ml) or control IgG1 
(20µg/ml). In the absence of anti-TGFβ antibody, LA-4/MLF co-cultured cells 
incubated with rHuKGF for 6 or 24 hours showed a significant increase in mRNA 
expression levels of SP-1, PAI-1, and elastin. Interestingly, rHuKGF incubated LA-
4/MLF co-cultured cells did not show upregulation of these genes when cells were 
treated with neutralizing anti-TGFβ antibody simultaneously, indicating that anti-



















Figure 29 - Murine AE2-like LA4 cells cocultured with mouse lung fibroblast (MLF)  
cells were incubated with rHuKGF (50 ng/ml) or PBS in the presence or absence of 
anti-TGFβ antibody (clone 1D11; 20 µg/ml) or control IgG1 (20 µg/ml) for 6 and 24 
hours, respectively. In LA-4/MLF co-cultures incubated with rHuKGF, significantly 
increased mRNA expression of SP-1 (A), PAI-1 (B), and) elastin  (C) were found at 
both time points which were almost completely blocked in the presence of 
neutralizing anti-TGFβ antibody (clone 1D11) but not in the presence of control IgG1 
at 6 and 24 hours, respectively. **P<0.05 versus the respective control group. 
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6 Discussion  
Pulmonary emphysema is considered as a progressive disease related to cigarette 
smoking and characterized by significant airflow limitation, which is related to reduced 
elastic recoil of the lung through parenchymal destruction as well as reduced elastic 
load applied to the airways through destruction of alveolar attachments (6). Although 
inflammation, oxidative stress, elastinolytic activity, and apoptosis of lung parenchymal 
cells are believed to contribute to the pathogenesis of emphysema, the precise 
mechanisms behind these pathological changes remain unclear. Until today, no 
effective treatment is available to re-establish normal gas exchanging lung 
parenchyma after emphysematous changes have been established. 
 
All-trans-retinoic acid (ATRA), a metabolite of retinol (vitamin A), which is a 
multifunctional modulator of cellular behaviour, may alter both extra-cellular matrix 
metabolism and normal epithelial differentiation in mammals such as the rat. Several 
reports have demonstrated that retinoic acid (RA), retinoic acid receptor (RAR), and 
retinoid X receptor (RXR) are intimately implicated in the process of differentiation of 
many types of cells, tissues, and organs including the lungs (189-190). Other than 
this, all-trans-retinoic acid enhances epithelial repairs and improves survival of alveoli 
in neonatal rats after lung injury by hyperoxic (191-192). 
 
About 10 years ago, Massaro and Massaro reported that normal lung structure can be 
restored in emphysematous rat lungs by therapeutic supplementation with all-trans-
retinoic acid (193). This report, therefore, dragged much attention and considerable 
interest on retinoic acid. In addition, a small study reported that supplementation of 
vitamin A can lead to improvement in pulmonary function in patients with moderate to 
severe COPD with reduced concentration of vitamin A in serum (194). Conversely, 
recent clinical assessments of the effect of all-trans-retinoic acid in emphysema 
patients were unable to present significant improvements (195). Retinoic acid failed to 
promote recovery from cigarette smoking induced emphysema in the guinea pig (196). 
In addition, retinoic acid has not been found to have a beneficial effect on the recovery 
from elastase induced emphysema in mice and Fischer 344 rat models (197-198). 
These studies raised concerns regarding a therapeutic role of retinoic acid in the 
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treatment of emphysema and suggest that the beneficial effect of retinoic acid 
treatment may be species specific.  
 
Very recently, Takahashi et al reported that simvastatin reverses elastase induced 
emphysema in mice by promoting alveolar epithelial cell proliferation as shown by a 
decrease in mean linear intercept (Lm) and increased PCNA positively stained 
alveolar epithelial cells in statin treated emphysematous lungs (199). Statin is a 3-
Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor which is known to reduce 
cholesterol. Besides this, statins exert multiple effects including anti-inflammatory 
effects, improved pulmonary function and improvement of coronary endothelial cell 
function in humans (200-201). However, morphologically, Takahashi et al focused only 
on the mean linear intercept to assess air space enlargement which is only one 
characteristic of emphysema and did not focus on the reversal of loss of alveolar gas 
exchange area. In addition, after lung injury, restoration of alveolar epithelial integrity 
requires proliferation, migration and differentiation of alveolar epithelial type 2 (AE2) 
cells. These aspects were not addressed in their study except proliferation of alveolar 
epithelial cells. Therefore, the induction of alveolar regeneration in emphysema has 
been emerged as a crucial need in this field. 
 
Repair and maintenance of an integer alveolar septal wall is achieved only if all tissue 
components of the lung are involved, the alveolar epithelium is particularly important 
as it interacts with various types of resident and mobile cells present in the alveolar 
interstitium including fibroblast cells and endothelium cells (202). Alveolar fibroblasts, 
which are the main cell type responsible for the synthesis and secretion of the main 
components of the alveolar extracellular matrix, seem to participate in the complex 
cellular interactions that lead to alveolar growth and multiplication both in the fetal lung 
(203) and in the adult lung. The interaction of AE2 cells with fibroblasts is important to 
the modeling of alveoles during lung morphogenesis (204) as well as during 
remodeling associated with alveolar repair following lung injury (205). In addition, AE2-
cell-derived factors may affect extracellular matrix formation by fibroblasts, such as 
stimulation of collagen type I secretion by AE2-cell-derived insulin-like growth factor 
(IGF) type 1 (206). Sirianni and coworkers (207) showed that direct intercellular 
contacts between alveolar fibroblasts and alveolar epithelial cells or capillary 
endothelial cells are greatly reduced in the emphysematous lung. Those results 
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suggest that pulmonary emphysema fibroblasts may lack the capacity to participate in 
the direct intercellular communications which play an essential role in fetal lung 
development and probably during lung repair (203, 208-209).  
 
Keratinocyte growth factor (KGF), one of the fibroblast-derived mitogen, promotes 
survival and induces proliferation, migration, and differentiation of cells that express its 
receptor, fibroblast growth factor receptor 2-IIIb (FGFR2-IIIb or KGFR). Hence, KGF 
has been shown to directly influence the morphologic appearance and phenotypic 
characteristics of a number of epithelial cell types during development and in adult life 
(103, 210-212). The therapeutic role of exogenous rHuKGF has shown favourable 
effects in dermal injury in porcine (105) and rabbit (210) models, in chemotherapy or 
irradiation-induced oral and gastrointestinal mucositis in mice (213), and in 
cyclophosphamide-induced ulcerative hemorrhagic cystitis in rats (214). Particulary, in 
lung, rHuKGF has been found to promote the proliferation of AE2 cell, which is a 
prominent feature associated with virtually all kinds of lung injury and is an essential 
element of lung repair (215).Thus, it was hypothesized that the supplementation of 
lung rHuKGF may represent a new therapeutic option for emphysema. 
 
The present study intended to evaluate, whether rHuKGF is able to induce a 
regenerative response in distal lung parenchyma after induction of pulmonary 
emphysema in mice. Mice were therapeutically treated at three occasions by 
oropharyngeal aspiration of 10 mg rHuKGF per kg b.w. after induction of pulmonary 
emphysema by PPE. Our result demonstrated the following: 1) exogenous rHuKGF 
supplementation drastically reversed respiratory dysfunction in contrast to 
emphysematous lungs, which was assessed by non invasive head-out body 
plethysmography; 2) induced airspace enlargement was partially reversed and lost 
alveolar gas exchange area was partially regenerated by rHuKGF supplementation in 
emphysematous lungs as assessed by tools of stereology; 3) the regenerative 
capacity of rHuKGF therapy was reflected by proliferation and differentiation of the 
major components of the alveolar wall which was associated with, A) increased 
expression of genes implicated in the formation of alveolar epithelium including PCNA, 
Cyclin D1, Nrf2, SP-C, AQP-5, Foxa-2, HGF and FGF-7; B) increased expression of 
genes implicated in capillary endothelium formation including VEGF, VEGFR1, 
VEGFR2; and C) increased expression of genes implicated in intertitial tissue 
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maintenance including TGFβ-1, TGFβ-2, TGFβ-R-1, TGFβ-R-2, Smad 2, PAI-1, SP-1, 
elastin and PDGF-A as assessed by quantitative real-time RT-PCR, Western blotting 
and immunohistochemistry techniques; 4) rHuKGF (50 ng/ml) induced TGFβ-1 mRNA 
expression levels in and release of active TGFβ-1 protein from primary mouse AE2 
cells, murine AE2-like cell line LA-4 and co-cultures of LA-4 and murine lung 
fibroblasts (MLF) in vitro but not in AE1-like cells E10 ; 5) recombinant TGFβ-1 protein 
(10 ng/ml) but not rHuKGF was able to induce elastin gene expression in MLF cells; 6) 
the induction of SP1, PAI-1, and elastin gene expression in LA-4/MLF co-cultures 
incubated with rHuKGF was completely blocked in the presence of neutralizing anti-
TGFβ antibody 1D11 (20 µg/ml). 
Taken collectively, our data demonstrate that exogenous supplementation of rHuKGF 
has the potential to induce alveolar maintenance programs in emphysematous mouse 
lungs. 
6.1 Effects of rHuKGF in in-vivo animal model 
As with the demonstration of a loss of alveolar structures in animal models of 
emphysema, the demonstration of alveolar regeneration can only be conclusive if 
appropriate parameters are chosen. Such quantitative morphological approach to 
assess emphysema has to comprise the estimation of both airspace enlargement 
and loss of the alveolar walls. Alveoli are composed of the alveolar airspace and the 
surrounding alveolar walls. As each alveolus has an opening towards the alveolar 
duct lumen and the alveolar wall typically separates adjacent alveoli. Therefore, a 
proper approach to assess airspace enlargement for each three-dimensional 
structure includes the estimation of mean chord length (MCL), absolute volume of air 
spaces (Vair) and alveolar surface area per unit volume (Sv). To assess the 
destruction of alveolar wall, quantification of absolute volume of septal tissue (Vast), 
alveolar surface area (Sa) and arithmetic mean thickness of alveolar septal wall (τast) 
are relevant (216). 
 
Results obtained from this study demonstrated an increase in mean chord length 
(MCL) and in absolute volume of air spaces (Vair) accompanied by a loss of alveolar 
surface area per unit volume (Sv) in elastase treated lungs (Fig.11) indicating towards 
elastase-induced air space enlargement. A significant reduction in alveolar surface 
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area in emphysematous lungs suggested that alveolar gas exchange area was 
decreased. On the other hand, volume of alveolar septal tissue (Vast) was not 
influenced by elastase treatment of lungs. Despite elastase treatment, this study 
showed that alveolar septal walls (τast) became thicker in emphysematous lungs 
(Fig.12). It is probable that after the periods of elastolysis, elastin and other 
extracellular matrix components are remodeled perhaps in disordered state in the 
areas where elastolysis has initiated emphysematous lesions, and thus contributing 
to increased alveolar septal wall thickness in emphysematous lungs. An increase of 
alveolar septal wall thickness is a known factor in suppressing the efficiency of 
alveolar gas exchange in emphysema and there are some strong evidences of 
increased thickness of alveolar septal wall with increased mean chord length in 
emphysematous lesions (217). 
 
Interestingly, rHuKGF significantly reduced enlargement of acinar air spaces (i.e. 
MCL) which was induced by elastase instillation. rHuKGF significantly induced 
alveolar surface area per unit volume (Sv) but did not alter the absolute volume of air 
spaces (Vair) in emphysematous lungs, which reflects that the reversal of air space 
enlargement was partial in emphysematous lungs (Fig.11). rHuKGF supplementation 
was associated with the improvement in alveolar gas exchange area as observed by 
a significant increase in absolute volume of alveolar septal tissue (Vast) and alveolar 
surface area (Sa) (Fig.12). Arithmetic mean thickness of the alveolar septal wall (τast) 
was also observed to be increased in rHuKGF treated emphysematous lungs 
(Fig.12). It is likely that after supplementation of rHuKGF in emphysematous lungs, 
there are periods of tissue repair and remodelling in which connective tissues 
undergo architectural rearrangement and thus contributing to an increase in 
thickness of the alveolar septal wall.    
 
In the present study, significant alterations in body weight in any of the tested groups 
were not observed (Fig.9A). Several hypotheses have been formulated to explain the 
mechanism of body weight loss in patients with emphysema including chronic 
inflammation, altered levels of the fat hormone leptin and breathing workload leading 
to negative energy balance. Long term cigarette smoke exposure leads to marked 
accumulation of inflammatory cells in lungs thus causing body weight alterations. On 
the other hand, the present study was designed to induce emphysema by PPE 
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aspirations. Although kinetic studies and analysis of mutant mice lacking 
inflammatory mediators have demonstrated that PPE not only possesses proteolytic 
activity but also leads to subsequent inflammation (218), the degree of inflammation, 
however, might be less in order to produce a marked variation in body weight in the 
present study. The finding from this study is in agreement with previous studies that 
have suggested that weight loss occurs in only a minority of emphysematous patients 
(219-220). Furthermore, supplementation of rHuKGF provided no alteration in total 
volume of right lung (VRL) in emphysematous lungs when compared to 
emphysematous lungs that received PBS (Fig.9B). On the other hand 
emphysematous lungs showed a significant increase in VRL compared to PBS treated 
lungs, which reflects diminished elastic recoil, a characteristic feature of emphysema 
(Fig.9B). Using non invasive head-out body plethysmography, it was observed that 
supplementation of rHuKGF significantly reversed the airflow limitation (reflected by 
EF50) when compared with control-treated emphysematous lungs indicating that 
rHuKGF has potential beneficial influence on increased airway resistance and 
pulmonary compliance (Fig.10). 
 
Alveolar repair events require alveolar cells of every type (epithelial, endothelial, and 
mesenchymal) to participate since the induction of equilibrated proliferation in a 
particular cell population of alveoli involves the simultaneous expansion of the each 
and every alveolar cell type. Re-epithelialization of airway and alveolar septal walls is 
one of the important components of each repair process in many types of lung injury. 
Results obtained from this study support the notion that rHuKGF has an important 
role in proliferate responses of epithelial cells by showing markedly up-regulated 
mRNA levels of PCNA, Cyclin D1 and Nrf2 (Fig.14). Proliferative cell nuclear antigen 
(PCNA), a marker for cell proliferation, is a cell cycle regulated nuclear protein whose 
rate of synthesis correlates with the proliferative rate of cells (221). In addition, PCNA 
immunoreactivity has been employed by many investigators as a tool to assess the 
proliferative potential of cell populations (222). Furthermore, significantly high 
induction of the expression of PCNA protein in emphysematous lungs which had 
received rHuKGF was observed (Fig.15) and could demonstrate by immunostaining 
for PCNA that the protein was highly expressed in alveolar and airway epithelial cells 
(Fig.13). In addition, Cyclin D1 is a nucleoprotein which controls the cell cycle 
progression through the G1 phase and the transition from G1 to S phase (223). The 
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G1 phase is the central phase to the integration of signals that regulate exit from the 
cell division cycle to differentiation and the reactivation of cell proliferation. Therefore, 
in emphysematous lungs, rHuKGF maintained the alveolar structure by inducing the 
mRNA expression of two genes that are already known to be functionally associated, 
as Cyclin D1 is thought to regulate the function of PCNA in DNA repair and 
replication (178). In addition, studies have shown a crucial role of nuclear factor 
erythroid-related factor 2 (Nrf2) in lung epithelial cell proliferation and protection 
against oxidative stress where mice lacking Nrf2 in alveolar epithelial cells (AE2) 
showed hindrance in the proliferation of AE2 cells leading to the conclusion that Nrf2 
is essential for proper proliferation on alveolar epithelial cells (179). Thus, the up-
regulation of PCNA, Cyclin D1 and Nrf2 expression by rHuKGF suggests that it plays 
a role in the coordination of the cell cycle and proliferation of epithelial cells with DNA 
replication and repair (Fig.14). 
 
The alveolar epithelium is composed of two morphologically and functionally distinct 
cell populations i.e. alveolar epithelial type 1 (AE1) and alveolar epithelial type 2 
(AE2) cells. AE2 cells are cuboidal cells that are the primary sites of surfactant 
synthesis and secretion. AE1 cells are thin, flat cells that line 90-95% of the gas 
exchange surface of the lung. AE2 cells serve as progenitor cells for the alveolar 
epithelium (202). The process of one differentiated cell type, such as AE2, 
undergoing transition into another differentiated cell type, such as AE1, has been 
referred to as differentiation. After lung injury and damage to AE1 cells, AE2 cells 
proliferate (as described above) and then differentiate into AE1 cells, which is an 
important process during restoration of the alveolar epithelium after injury. rHuKGF 
has been shown to promote AE2 cell proliferation in rats both in vitro and in vivo 
(126, 164). rHuKGF has the unique ability to induce differentiation of AE2 cells in 
vitro suggesting a role for rHuKGF in repair of the alveolar epithelium following lung 
injury (141, 224).  Similarly, in this study the important role of rHuKGF in promoting 
the alveolar epithelium differentiation was observed. The increase in whole lung 
mRNA for the surfactant protein-C (SP-C) (2.2x) was induced by rHuKGF (Fig.16A), 
which may relate to an increase in the number of AE2 cells expressing this protein 
(224). SP-C is a hydrophobic polypeptide which is involved in the regulation of the 
biophysical acitivity of the alveolar surfactant lining layer (225-226). Expression of 
SP-C is thought to be restricted to AE2 cells in the adult animal (180-181). Next 
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investigation comprises the expression of the AE1 cell specific marker, aquaporin 
(AQP)-5 (Fig.16B), which is a mercury-sensitive water channel in salivery, lacrimal 
and repiratory tissues (227) and is a member of the large family of aquaporin 
proteins, most of which are water channels. (228-229). In adult alveolar epithelium, in 
situ studies suggest that AQP-5 is expressed only on the apical surface of AE1 cells 
(230). AQP-5 contributes to alveolar fluid homeostasis and cell volume regulation via 
its role as a water channel (229). Results obtained from this study showed a 
significant induction in the expression of AQP-5 in rHuKGF treated emphysematous 
lungs (Fig.16B) which clearly indicates that rHuKGF promoted transdifferentiation of 
AE2 cells into AE1 cells. In this study, an increase in the expression of Foxa-2, a fork 
head transcription factor was observed in rHuKGF treated emphysematous lungs 
(Fi.16C). Foxa-2 was shown previously to regulate cell differentiation in many organs, 
including the lung, pancrease and liver (231-234). An electron microscopic study on 
fetal mouse lung morphology revealved that disruption of Foxa-2 in the fetal mouse 
lung leads to immaturation of AE2 cells with lack of their characteristic morphology 
such as lamellar bodies and sparse apical microvilli, as well as absence of AE1 cells 
suggesting its important role in the regulation of lung epithelial cells differentiation 
(184). In the same study, in Foxa-2 deleted fetal mouse lung, immunostaining for 
alveolar epithelial cells differentiation markers, SP-B and SP-C were found to be 
absent in immature AE2 cells indicating that Foxa-2 is essential for epithelial cell 
differentiation during lung morphogenesis (184). Recent studies showed that 
conditional deletion of Foxa-2 in the mouse lung epithelial cells leads to airspace 
enlargement reflecting its requirement for normal alveolarization and postnatal lung 
homeostasis (232). Ectopic expression of Foxa-2 in distal respiratory epithelial cells 
in the lungs of transgenic mice disrupts branching morphogenesis and arrests 
differentiation of peripheral epithelial cells, suggesting its potential role in lung 
formation (183). This finding suggests that the administration of rHuKGF in 
emphysematous lung has a potential role in the process of epithelial cells 
differentiation.  
 
Hepatocyte growth factor (HGF) and fibroblast growth factors-7 (FGF-7) stimulate 
alveolar epithelial cells proliferation, migration and differentiation. It has been shown 
that HGF facilitates the repair of an experimental epithelial wound in vitro (235). In 
                                                                                      
 80 
lung, HGF and FGF-7 are relevant as both the factors have been demonstrated to be 
protective in a number of animal models of acute lung injury (236).  
Moreover, it has been demonstrated that HGF plays a pulmotropic role in 
compensatory lung regeneration after pneumonectomy (237). A defect in HGF 
production by neighboring fibroblasts could contribute to the excessive apoptosis of 
epithelial and endothelial cells, which is now recognized as an important step in the 
constitution of emphysema. The role of HGF in COPD has been addressed by two 
previous studies. Plantier and colleagues (238) found that cultured fibroblasts 
harvested from patients with emphysema produced less HGF than controls, and 
Bonay and colleagues (239) found a direct relationship between the severity of 
airflow obstruction and HGF mRNA content in lung samples of smokers. Therefore, 
these two studies suggest that the pulmonary regulation of HGF may be abnormal in 
patients with COPD. Recently, Ishizawa et al (240) showed that the intraperitoneal 
recombinant human HGF abrogates elastase-induced emphysema in mice through 
the mobilization of endothelial precursor cells and their engraftment in the damaged 
alveoli. This study also reports the significant high levels of HGF and FGF-7 which 
are essential mediators of alveolar repair, by lung fibroblasts, in emphysematous 
lungs receiving rHuKGF therapy (Fig.17A-B).  
 
Vascular endothelial growth factor (VEGF), also known as vascular permeability 
factor (VPF) (241), is a 34–46 kDa glycoprotein that was first isolated from tumour 
cells. VEGF plays a fundamental role in physiological and pathophysiological forms 
of angiogenesis, which is the growth of new blood vessels from existing ones, and 
regulation of endothelial cell differentiation (158) VEGF165 is the predominant isoform 
and the most highly expressed isoform in the human lung where it is produced mainly 
by epithelial cells (242). VEGF165 is the most biologically active in the physiological 
state (243). 
The lung contains the highest level of transcripts (244) amongst a wide range of 
organs that express VEGF. Lung VEGF is synthesized by alveolar epithelial cells, 
bronchial epithelial cells, smooth muscle cells, and alveolar macrophages (245-246). 
VEGF is necessary for the formation of vascular beds of several organs during 
embryo development and coordinates essential interactions between airway and 
blood vessels that are required for the establishment of normal lung architecture, as 
demonstrated by the lethality of VEGF knockout mice and abnormal vasculogenesis 
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of the heart and large vessels with loss of only a single copy of the VEGF gene (247). 
VEGF signals through receptors VEGFR-1 and VEGFR-2. VEGFR-1 plays a role in 
the organization of development of embryonic blood vessels (248) and in enhanced 
monocyte adhesion to endothelial cells (249) 
It has been shown that VEGF and VEGFR2 levels were decreased in the lung of 
emphysematous subjects compared to healthy controls (250) and were related to 
increased alveolar cell apoptosis. Inhibition of VEGFR-2 with chemical inhibitor 
SU5416 in rats leads to enlargement of the air spaces, alveolar septal cell apoptosis, 
and decreased capillary density, which are the features of emphysema (82). VEGF 
also plays an important role in postnatal lung growth, since blockade of VEGFR-2 
and VEGFR-1 with DC101 (an antibody to VEGFR-2), and MF1 (an antibody to 
VEGFR-1) respectively, arrests lung growth and leads to an emphysematous mouse 
phenotype (251). These studies certainly support the known role of VEGF in 
vasculogenesis during embryonic and early life. In this study, the expression of VEGF 
and its receptors as well as protein expresson of VEGFR2 was significantly induced 
in rHuKGF received emphysematous lungs, suggesting its effects on pulmonary 
capillary endothelium formation (Fig.19A-C, Fig.20). This finding was also paralleled 
by the induced proliferation of capillary endothelium cells in rHuKGF administered 
emphysematous lungs as assessed by co-localization of Ki-67 and markers for 
endothelial cells (podocalyxin) (Fig.18A-C). 
 
Extracellular matrix (ECM) plays a crucial role during the lung development as it 
regulates cellular growth, migration and differentiation processes (252). Transforming 
growth factorβ-1 (TGFβ-1) has been implicated as a key mediator to promote the 
synthesis, accumulation and repair of interstitial tissue (185). This action is exerted 
through two complementary pathways, one which reduces matrix degradation and 
anotherone which stimulates matrix accumulation (253-254). The TGFβ-signaling 
pathway is crucial in the regulation of the transcription of genes involved in interstitial 
tissue remodeling and repairs. The TGFβ-1 signal is transduced by the 
transmembrane serine-threonine kinase receptor TGFβ-R-1, TGFβ-R-2 and the 
cytosolic protein Smad 2 to the nucleus where this complex binds to DNA and 
regulates gene transcription (151). The TGFβ-1 signaling pathway also plays an 
important role in the maintenance of alveolar structure, promotes pulmonary 
alveologenesis and preventing emphysematous pathogenesis (255-256). In the 
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present study, it was observed that rHuKGF significantly induced expression of 
TGFβ-1, TGFβ-R-1, TGFβ-R-2 and Smad 2 in emphysematous lungs (Fig.22A-C, 
Fig.24B). This was associated with a high expression of ECM proteinase inhibitor 
PAI-1, which inhibits ECM degradation, and zinc finger transcription factor (SP-1) 
expression that regulates the transcription of TGFβ-1 in rHuKGF received 
emphysematous lungs (Fig.23A-B). It has been reported that TGFβ-1 up-regulates 
the expression of PAI-1 (186), which reflects that TGFβ-1 contributes to the inhibition 
of ECM degradation. 
 
It was noticed that rHuKGF exerted a positive effect on interstitial tissue formation by 
inducing elastin expression in emphysematous lung tissue (Fig.22D). Elastin is a 
structural protein of the ECM which confers elastic properties on the pulmonary 
alveolar interstitium and remains distributed broadly within the alveoli, including the 
alveolar septae, septal junctions, and along the septal-free edges (257). Organisation 
of elastin is inextricably linked to the proper alveolar development. Destruction of 
elastin is implicated in thinning and weakening of the alveolar walls that leads to 
tissue destruction and abnormal expansion of air sacs. (258). Therefore, elastic fibre 
formation and deposition are critical for alveologenesis which is characterized by the 
development of septae that subdivide the terminal air sacs into mature alveoli. This 
process requires the elastin expression by alveolar myofibroblasts at the tips of the 
developing alveolar septae. (259-260). Mice deficient for elastin (Eln–/–) revealed 
arrested perinatal development of terminal airway branches, resulting in dilated distal 
air sacs with attenuated tissue septae, a condition characteristic of emphysema 
(261).  
 
It has been demonstrated that bronchial epithelial cells can produce TGFβ-2 at levels 
that alter gene expression and migration of fibroblasts (262-263). Furthermore, it has 
been shown that epithelial derived TGFβ-2 plays a critical role in modulating the 
basal structure of interstitial tissue and maintains collagen homeostasis using in vitro 
model of epithelial-mesenchymal trophic unit in the human airways. The epithelial-
mesenchymal trophic unit consists of opposing layers of epithelial and mesenchymal 
cells. The area between these two cell layers, the basement membrane zone, 
contains extracellular matrix and a network of nerve fibers. 
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The novel finding in this study is the increase in mRNA expression of TGFβ-2 by 
administration of rHuKGF in emphysematous lungs. Further support for a role for 
TGFβ-2 comes from the demonstration that there are increased numbers of TGFβ-2 
expressing cells as assessed by immunohistochemical staining in emphysematous 
lungs receiving rHuKGF therapy (Fig.24A, D). Hence, this data indicates that TGFβ-2 
may be contributing to the formation of interstitial tissue along with the contribution of 
TGFβ-1 to the process which is vital for the repair process after lung injury. 
 
Platelet-derived growth factor (PDGF) was originally identified as a mitogen for 
smooth muscle cells, fibroblasts, and glia cells. Smooth muscle cells are situated at 
three locations in the lung, in vascular and bronchial walls, and in alveolar septae 
(264). Alveolar septal smooth muscle cells, which are also known as contractile 
interstitial cells or alveolar myofibroblasts (265), have the morphology of fibroblasts 
and they express alpha-smooth muscle actin (266). Study based on the alpha-
smooth muscle actin stainings in the lung parenchyma of platelet-derived growth 
factor-alpha (PDGF-A) null mice revealed a profound deficiency in alveolar 
myofibroblast. Alveolar myofibroblasts are responsible for the deposition of alveolar 
septal elastin and are crucial for alveolar septal formation during lung development. 
Our results indicate that rHuKGF has a capacity to significantly induced transcript 
levels of PDGF-A in pulmonary emphysematous lungs that contribute to the alveolar 
repair (Fig.25). 
 
Collectively, this study suggests that rHuKGF leads to alveolar maintenance 
programs in emphysematous lung through exerting a major positive effect on 
interstitial tissue formation and maintenance. 
 
Earlier, protective effects of rHuKGF pre-treatment have been reported by Plantier 
and colleagues in elastase induced emphysema in mice (267). However, in contrast 
to the findings from the present study, these authors did not observe a curative effect 
of rHuKGF in the reversal of elastase induced emphysema when therapy was 
initiated after establishment of the disease. The discrepancy of their data to the 
results obtained from the present study may be related to the following reasons: 
Firstly, they supplemented mice with only 5 mg rHuKGF per kg b.w. whereas others 
have shown that proliferation of AE2 cells depends on the dose of rHuKGF applied. A 
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dose of 10 mg rHuKGF per kg b.w., which was used in the present study, has been 
proven to promote proliferation of AE2 cells to a maximal degree as assessed by SP-
B immunohistochemical staining in mice (135). Secondly, Plantier and co-workers 
instilled rHuKGF via a subcutaneous route whereas intratracheal administration of 5 
mg rHuKGF per kg b.w. has been confirmed to stimulate more potent and more 
lasting alveolar epithelial cell proliferation in rodents (268). Independently, our group 
demonstrated that the proliferation of AE2 cells was significantly increased via 
oropharyngeal aspiration compared with intratracheal instillation using 10 mg 
rHuKGF per kg b.w. in C57BL/6 mice (269). Third, Plantier and co-workers 
supplemented mice with rHuKGF continuously from day 21 till day 27 and sacrificed 
mice at day 27 after elastase instillation. The kinetics studies of the incorporation of 
5-bromo-2'-deoxyuridine (BrdU) into alveolar epithelial cells in rats showed that 
proliferation of AE2 cells peaks at ~2-3 days after treatment with intratracheally given 
rHuKGF (126). Additionally, Fehrenbach and co-workers showed that a significant 
portion of hyperplastic AE2 differentiated into AE1 cells after day 3 following rHuKGF 
instillation (127). Moreover, in vitro studies have revealed that the continous 
presence of rHuKGF to AE2 cells leads to hindrance in AE 2 cells differentiation to 
AE1 cells (182). Hence, the present study indicates that the therapeutic aspects of 
rHuKGF to favourably affect emphysematous related changes is attributable to the 
supplementation of 10 mg rHuKGF per kg b.w. at three occasions with the time gap 
of three days via oropharyngeal aspiration. 
6.2 Effects of rHuKGF in in-vitro cell culture 
The gene expression and protein synthesis for TGFβ-1 have been documented in 
embryonic and adult murine lung (154, 270), but relatively little is known about the 
precise cells expressing this gene. The previous study has shown that TGFβ-1 is 
localized to airway epithelial and AE2 cells in normal human and murine lung tissue 
(147).  
Likewise, in the present study, it was observed that rHuKGF greatly increased the 
numbers of TGFβ-1 immunostained alveolar and airway epithelial cells (Fig.21). 
Interestingly, in-vitro cell culture, TGFβ-1 mRNA expression was found to be induced 
in primary mouse AE2 cells and in the murine AE2-like cell line LA-4 by incubation 
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with rHuKGF (Fig.26) as well as the release of active TGFβ-1 protein from primary 
mouse AE2 cells and LA-4 cells was found to be significantly increased (Fig.27).  
 
Furthermore, TGFβ is a chemoattractant for fibroblasts and can exert mitogenic 
effects on pulmonary fibroblasts via cytokines secreted by alveolar macrophages and 
fibroblasts including platelet-derived growth factor (PDGF) (271). In addition, it 
induces the transcription and synthesis of various other components of the 
extracellular matrix by immature and mature pulmonary fibroblasts, such as 
fibronectin, glycosaminoglycans, and proteoglycans (272, 273). 
 
It has been demostrated that in lung and dermal fibroblasts, TGFβ increases elastin 
mRNA levels (153, 274). Further, in cultured human lung fibroblast, TGFβ induced an 
increase in mRNA and protein levels of elastin (148). Besides, it has been 
demonstrated that mice deficient in Smad 3 or the β6-integrin develop air space 
enlargement which indicating the influence of TGFβ-signaling for the deposition of 
elastin in alveolar structures (152). Smad 3 is a component of the TGFβ signal 
transduction pathway and deficiency of Smad 3 leads to repression of tropoelastin 
(precursor of elastin) expression in lung, and the development of centrilobular 
emphysema (152). Moreover, β6-integrin is involved in TGFβ activation. β6-integrin 
converts latent TGFβ protein to an active form hence allowing it to bind to its cognate 
receptors (275). These observations suggest that lung fibroblasts under the influence 
of active TGFβ are required for elastin accumulation in interstitial tissue of alveolar 
structures. 
Likewise, in the present study, an induction of elastin gene expression as well as 
induced mRNA levels of SP-1, PAI-1 and TGFβ-1 were observed in murine lung 
fibroblast (MLF) cells by recombinant TGFβ-1 protein. Whereas rHuKGF did not 
affect mRNA expression of TGFβ-1, SP1, PAI-1, and elastin in MLF cells cultured 
alone suggesting that it’s TGFβ-1 but not rHuKGF which induces increased mRNA 
expression of genes implicated in TGFβ-1 pathway in MLF cells (Fig.28). 
 
Interestingly, incubation of co-cultures of MLF cells and AE2-like murine LA-4 cells 
with rHuKGF for 24 hours resulted in an approximately 10-fold increased release of 
active TGFβ-1 into the supernatant suggest that the beneficial effect of rHuKGF in 
interstitial tissue compartment of lung is related to AE2 cell-derived TGFβ-1 (Fig.27). 
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This finding was further confirm by observing that if TGFβ-signaling was completely 
blocked in the presence of the anti-TGFβ neutralizing antibody 1D11, rHuKGF failed 
to increase mRNA expression levels of elastin, SP-1 and PAI-1 in the MLF/LA-4 co-
culture system, thus highlighting the importance of TGFβ release into the medium to 
mediate the effect of rHuKGF on interstitial tissue maintenance (Fig.29). 
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7 Conclusions 
The presented thesis work provides a broad and novel overview on the therapeutic 
effect of rHuKGF supplementation on elastase induced pulmonary emphysema in 
mice. This study obtained with lung function test and using tools of morphometry, 
clearly suggested that the exogenous rHuKGF supplemented emphysematous lungs 
had greatly improved lung function and regenerated alveolar gas exchange area, 
which were found to be lost in emphysematous lungs. Upon validation on the 
molecular level, genes that are associated with biological processes implicated in the 
repair of alveolar gas exchange area including alveolar epithelial, capillary endothelial 
and extracellular matrix (ECM) formation, were favourable expressed as per the 
exogenous rHuKGF supplementation in emphysematous lungs in comparison with 
control treated emphysematous lungs. 
 
In in-vitro cell culture, rHuKGF induced the expression of TGFβ-1 in and release of 
active TGFβ-1 from primary mouse AE2 cells, murine AE2-like cells LA-4 and co-
cultures of LA-4 and murine lung fibroblasts (MLF). Recombinant TGFβ-1 protein but 
not rHuKGF was found to increase elastin gene expression in MLF cells. The 
importance of TGFβ-signaling as a potential mediator of the AE2-linked effects of 
rHuKGF on the interstitial tissue compartment was investigated in LA-4/mouse lung 
fibroblast (MLF) co-cultures in the presence or absence of the neutralizing anti-TGFβ 
antibody 1D11. Blockade of TGFβ-signaling by neutralizing antibody abrogates 
rHuKGF induced SP-1, PAI-1 and elastin expression in LA-4/MLF co-cultures.   
 
Taken together, firstly, the result from mice body weight measurement suggests that 
neither elastase nor rHuKGF had an influence on the health status of mice. 
Interestingly, results obtained from lung function test and quantitative morphologic 
methods suggest that exogenous supplementation of rHuKGF exerts therapeutic 
effects in pulmonary emphysema by promoting the regeneration of alveolar 
epithelium in lung. Furthermore, genes implicated in alveolar epithelial, capillary 
endothelial and intertitial tissue formation were found to be significantly induced 
because of the exposure of rHuKGF in emphysematous lungs suggests its 
therapeutic potential role to induce alveolar maintenance programs in 
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emphysematous lungs. The presented study further suggests that the regenerative 
effects of rHuKGF on the interstitial tissue compartment are linked to AE2 cell-






Figure 30 - A. rHuKGF promotes alveolar structural maintenance programs in 
emphysematous lungs by inducing proliferation of a) alveolar epithelium, b) capillary 
endothelium, and c) interstitial tissue. B. The data suggests that rHuKGF has the 
potential to induce AE2 cell-derived TGFβ-1 being particularly important for 
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ATS American Thoracic Society 
AQP-5 Aquaporin-5 
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C.A.S.T.  Computer assisted stereological toolbox   
°C Degree celcius 
cDNA Complementary DNA 
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COPD Chronic obstructive pulmonary disease 
Ct Cycle threshold 
DAB 3, 3`-diaminobenzidintetrahydrochloride 
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ECM    Extracellular matrix 
EF50  Mid expiratory airflow 
ELISA Enzyme-linked immunosorbent assay 
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Mg Milligram 
Ml Millilitre 
MLF Mouse lung fibroblast 
mm  Millimeter 
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pH Potential of hydrogen 
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RT Reverse transcription 
Rtase Reverse transcriptase 
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10 Summary 
Pulmonary emphysema is a major manifestation of chronic obstructive pulmonary 
disease (COPD), which is characterized by persistent inflammation and progressive 
alveolar destruction. Such destruction in the distal respiratory tract is thought to be 
irreversible. Despite promising initial experiments using all-trans retinoic acid (ATRA) 
supplementation to reverse emphysema in rats, contradictory results were obtained 
by others. A number of studies have shown that the instillation of recombinant human 
keratinocyte growth factor (rHuKGF) into the lung protects animals from acute lung 
injury and favourably influences alveolar maintenance and repair. The mechanism of 
protection, however, is not completely understood.  
 
This study aimed at investigating the potential of rHuKGF to induce alveolar 
regeneration. Two sets of experiments were performed: 1) an in-vivo study to 
evaluate the therapeutic effects of rHuKGF in the elastase-induced pulmonary 
emphysema mouse model; 2) an in-vitro study to elucidate the basic molecular 
mechanism underlying the therapeutic effect of rHuKGF. 
 
In-vivo experiments:  
Lung emphysema was induced in C57BL/6 male mice by two oropharyngeal 
aspirations of porcine pancreatic elastase (PPE, 2.25 mg/kg b.w., day 0, 10) versus 
saline (PBS-group) into the lungs. To evaluate the regenerative effect of rHuKGF, 
PPE treated mice received oropharyngeal aspirations of rHuKGF (PPE+KGF, 
10 mg/kg b.w.) versus saline (PPE+PBS) at day 31, 34, and 37, respectively. Initially, 
lung function was assessed at day 31 (PBS versus PPE) or day 40 (PPE+PBS 
versus PPE+KGF) by non invasive head-out body plethysmographic measurement of 
mid-expiratory airflow (EF50). At day 31 or 40, lungs were prepared for analyses of 
immunohistochemistry, quantitative morphometry, quantitative real time reverse 
transcriptase-polymerase chain reaction (RT-PCR), and Western blotting techniques. 
The statistical significance of differences between groups was assessed by using t-
test or non-parametric U-test. 
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Regeneration is a complex process involving periods of cellular proliferation, 
differentiation and extracellular matrix (ECM) synthesis and remodeling. Interestingly, 
rHuKGF therapy significantly reversed respiratory dysfunction induced by PPE 
application: PBS-group: 100%; PPE-group: 66%; control treatment (PPE+PBS)-
group: 53%; therapeutic treatment (PPE+KGF)-group: 98%. This was accompanied 
by partial reversal of airspace enlargement and partial regeneration of alveolar gas 
exchange area as assessed by design based stereology. 
 
Analyses in whole lung tissue homogenate demonstrated that the beneficial effect of 
rHuKGF was associated with increased mRNA expression of genes involved in: a) 
proliferation of epithelium, i.e. PCNA, Cyclin D1 and Nrf2; b) differentiation of alveolar 
epithelium, i.e. SP-C; AQP-5 and Foxa-2 as well as HGF and FGF-7 which possess 
mitogenic effect on alveolar epithelium; c) formation of capillary endothelium, i.e. 
VEGF and its specific receptors VEGFR1 and VEGFR2; d) maintenance of interstitial 
tissue, i.e. TGFβ-1, TGFβ-2, TGFβ-R-1, TGFβ-R-2, Smad 2, PAI-1, SP-1, elastin and 
PDGF-A. 
 
Furthermore, Western blot analysis and immunohistochemistry for PCNA revealed 
that therapeutic application of rHuKGF resulted in a prominent increase of the 
proliferation of alveolar and airway epithelial cells in emphysematous lungs. 
Therapeutic administration of rHuKGF was associated with increased capillary 
endothelial cell proliferation as assessed by double immunohistochemistry for Ki-67 
and podocalyxin. Besides, an increase in the protein level of VEGFR2 was revealed 
by Western blot analysis. 
 
In addition, rHuKGF therapy induced the expression of TGFβ-1 and TGFβ-2 proteins 
in alveolar as well as airway epithelial cells as assessed by immunohistochemistry. 
TGFβ-1 and TGFβ-2 are implicated in the regulation of interstitial tissue formation.  
 
In-vitro experiments: 
In order to proof that the stimulating effects of rHuKGF on the expression of elastin 
observed in vivo were mediated via alveolar epithelial type 2 cells (AE2) derived 
TGFβ-1, primary AE2 cells isolated from C57BL/6 mouse lungs, murine AE2-like cell 
line LA-4 and AE1-like cell line E10, murine embryonic lung fibroblast cell line MLF, 
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and LA-4/MLF co-cultures were incubated with rHuKGF (50 ng/ml), recombinant 
TGFβ-1 protein (10 ng/ml) or PBS in the presence or absence of anti-TGFβ-
neutralizing antibody (clone 1D11, 20 µg/ml)) or control IgG. After 6 hrs and 24 hrs, 
cells were collected for mRNA expression analysis by means of quantitative real time 
reverse transcriptase-polymerase chain reaction (RT-PCR). Supernatants were 
analysed by ELISA for activated TGFβ-1 protein. 
 
TGFβ-1 was evaluated as a potential mediator of AE2-linked regenerative effect of 
rHuKGF on the interstitial tissue compartment in the lung. rHuKGF induced the 
expression of TGFβ-1 in and release of active TGFβ-1 from primary mouse AE2 
cells, murine AE2-like cells LA-4 and co-cultures of LA-4/MLF but not in murine AE1-
like cells E10. Recombinant TGFβ-1 protein but not rHuKGF was found to induce 
elastin gene expression in MLF cells. Additionally, blockade of TGFβ-signaling by 
neutralizing anti-TGFβ-antibody 1D11 abrogates rHuKGF induced mRNA expression 
levels of SP-1, PAI-1 and elastin in LA-4/MLF co-cultures.  
 
Taken collectively, the results from this study suggest that therapeutic application of 
exogenous rHuKGF into emphysematous lungs is able to induce alveolar 
maintenance programs in the emphysematous mouse lung and that alveolar 
epithelial type 2 cells (AE2) derived TGFβ-1 is involved in these processes. 
Therefore, it is suggested that rHuKGF has a potential as therapeutic agent in the 
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11  Zusammenfassung 
Das Lungenemphysem ist eine der wichtigsten Ausprägungen chronisch obstruktiver 
Lungenerkrankungen (COPD), die durch eine persistierende Entzündung und eine 
fortschreitende Zerstörung der Lungenalveolen gekennzeichnet sind. Eine solche 
Zerstörung des für den Gasaustausch zuständigen distalen Atemwegtraktes wurde 
bislang als irreversibel eingestuft. Trotz initial viel versprechender Experimente, bei 
denen eine Supplementierung mit All-trans-Retinolsäure (ATRA) eingesetzt wurde, 
um ein Lungenemphysem bei der Ratte umzukehren, erbrachten Folgestudien 
anderer Arbeitsgruppen widersprüchliche Resultate. Durch zahlreiche 
Untersuchungen konnte belegt werden, dass eine intratracheale Instillation von 
rekombinantem humanen Keratinozyten-Wachstumsfaktor (rHuKGF) in die Lunge vor 
einem akuten Lungenschaden schützt und sich günstig auf die Aufrechterhaltung und 
Reparatur alveolärer Strukturen auswirkt. Dieser Schutzmechanismus ist jedoch 
noch nicht gänzlich entschlüsselt. 
 
Das Ziel dieser Untersuchung war es, dass Regenerationspotential von rHuKGF in 
alveolärem Gewebe zu erforschen. Zwei experimentell Ansätze wurden durchgeführt: 
1) eine in-vivo Studie zur Beurteilung des therapeutischen Effektes von rHuKGF im 
Mausmodell beim Elastase-induzierten Emphysem; 2) eine in-vitro Studie zur 
Charakterisierung der molekularen Mechanismen, die dem therapeutischen Effekt 
von rHuKGF zugrundeliegen.  
 
In-vivo Experimente: 
Ein Lungenemphysem wurde bei männlichen C57BL/6-Mäusen durch zweimalige 
oropharyngeale Aspiration von Pankreaselastase des Schweins (PPE-Gruppe; 2,25 
mg/kg Körpergewicht; Tag 0, 10) in die Lunge ausgelöst; eine Kontrollgruppe erhielt 
eine entsprechende Gabe von Kochsalzlösung (PBS-Gruppe). Um einen 
therapeutischen Effekt von rHuKGF zu prüfen, erhielten mit PPE behandelte Mäuse 
oropharyngeale Applikationen von rHuKGF (PPE+KGF-Gruppe, 10 mg/kg KG) bzw. 
Kochsalzlösung (PPE+PBS-Gruppe) an den Tagen 31, 34 und 37. Zunächst wurde 
ein Lungenfunktionstest vorgenommen, was an Tag 31 (PBS versus PPE) bzw. an 
Tag 40 (PPE+PBS versus PPE+KGF) mittels nicht-invasiver head-out body 
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plethysmographischer Messung des mittleren exspiratorischen Atemflusses (EF50) 
erfolgte. Anschließend wurden die Lungen an Tag 31 bzw. 40 für Analysen mittels 
Immunhistochemie, quantitativer Morphometrie, quantitativer Reverse Transkriptase-
Polymerase-Kettenreaktion (RT-PCR) und Western Blotting aufbereitet. Unterschiede 
zwischen den experimentellen Gruppen wurden mittels t-Test oder nicht-
parametrischem U-Test auf Signifikanz geprüft. 
 
Regeneration ist ein komplexer Vorgang, der Phasen der Zellproliferation und 
Differenzierung sowie der Synthese und des Umbaus extrazellulärer Matrix (ECM) 
umfasst. Bemerkenswerterweise führte die therapeutische Gabe von rHuKGF zu 
einer signifikanten Verbesserung der nach PPE-Gabe festgestellten, respiratorischen 
Dysfunktion: PBS-Gruppe: 100%; PPE-Gruppe: 66%; Kontrollbehandlungs- 
(PPE+PBS-) Gruppe: 53%; Therapie- (PPE+KGF-) Gruppe: 98%. Dieser Effekt ging 
einher mit einer partiellen Aufhebung der Vergrößerung der distalen 
Gasaustauschräume und einer partiellen Regeneration der alveolären 
Gasaustauschfläche, was mit Hilfe von Methoden der design-based stereology 
beurteilt wurde.  
 
Die molekularbiologischen Analysen an Lungengewebehomogenat ergaben, dass 
der regenerative Effekt von rHuKGF mit einer erhöhten mRNA-Expression von 
Genen assoziiert war, die an folgenden Prozessen beteiligt sind: a) Proliferation, z.B. 
PCNA, Cyclin D1, Nrf2); b) Epithelzelldifferenzierung, z.B. SP-C, AQP-5 und Foxa-2, 
sowie HGF und FGF-7; c) Kapillarendothel-Bildung, z.B. VEGF und seine 
spezifischen Rezeptoren VEGFR1 und VEGFR2; d) Bildung extrazellulärer Matrix, 
z.B. TGFβ-1, TGFβ-2, TGFβ-R-1, TGFβ-R-2, Smad2, PAI-1, SP-1, Elastin und 
PDGF-A. 
 
Außerdem konnte mittels Western Blotting und Immunhistochemie für PCNA gezeigt 
werden, dass die therapeutische Gabe von rHuKGF bei emphysematösen Lungen zu 
einem ausgeprägten Anstieg der Proliferation von Alveolar- und Atemwegsepithel 
führt. Die therapeutische Gabe von rHuKGF war einerseits mit einer erhöhten 
Zellproliferation von Kapillarendothel verbunden, wie mit Immunhistochemie für Ki-67 
und Podocalyxin gezeigt wurde. Andererseits bewirkte sie eine erhöhte 
Proteinkonzentration des VEGFR2, wie es anhand von Western Blots zu erkennen 
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war. Zusätzlich erbrachten immunhistochemische Untersuchungen, dass durch die 
Therapie mit rHuKGF die Expression von TGFβ-1- und TGFβ-2-Proteinen, welche 
die Bildung der extrazellulären Matrix steuern, in Alveolar- und 
Atemwegsepithelzellen induziert wird. 
 
In vitro Experimente: 
Um zu überprüfen, ob die stimulierende Wirkung von rHuKGF auf die Expression von 
Elastin, die in den in-vivo Experimenten gesehen wurde, über Alveolarzellen vom 
Typ 2 (AE2) mittels TGFβ-1 vermittelt werden, wurden AE2-Zellen aus C57BL/6 
Mäuselungen, murine AE2-ähnliche Zelllinie LA-4, die AE1-ähnliche Zelllinie E10, die 
murine embryonale Lungenfibroblasten-Linie MLF und LA-4/MLF Co-Kulturen mit 
rHuKGF (50 ng/ml), rekombiniertem TGFβ-1 Protein (10 ng/ml) oder PBS in 
Anwesenheit oder Abwesenheit von anti-TGFβ-neutralisierendem Antikörper (Klon 
1D11, 20 µg/ml)) bzw. Kontroll-IgG inkubiert. Nach sechs und 24Stunden wurden die 
Zellen für die mRNA Expressionsanalyse mit Hilfe quantitativer Reverse 
Transkriptase-Polymerase-Kettenreaktion (RT-PCR) gesammelt. 
 
Des Weiteren wurde geprüft, ob TGFβ als potentieller Mediator des regenerativen 
Effekts von rHuKGF auf interstitielles Lungengewebe gewertet werden kann. 
Mehrere Hinweise unterstützen die Annahme, dass TGFb in diesem Zusammenhang 
eine wichtige Rolle zukommt.  rHuKGF induziert die Expression von TGFβ-1 in und 
die Ausschüttung von aktivem TGFβ-1 aus AE2-Mauszellen, murinen AE2-ähnlichen 
Zellen LA-4 und den Co-Kulturen von LA-4/MLF, nicht aber aus murinen AE1-
ähnlichen Zellen E10. Rekombinantes TGFβ-1, nicht aber rHuKGF, induzierte die 
Genexpression von Elastin in MLF Zellen. Zusätzlich hebt die Blockade des TGFβ-
Signalweges mittels neutralisierendem anti-TGFβ-Antikörper 1D11, die rHuKGF-
induzierte mRNA-Expression auf der Ebene von SP-1, PAI-1 und Elastin in LA-4/MLF 
Co-Kulturen auf. 
 
Zusammengefasst zeigen die Ergebnisse dieser Studie, dass die therapeutische 
Gabe von exogenem rHuKGF in emphysematösen Lungen Mechanismen induzieren 
kann, die für die Erhaltung alveolärer Strukturen von wesentlicher Bedeutung sind 
und dass Alveolarepithelzellen vom Typ2 über die Freisetzung von TGFβ-1 in diesen 
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Prozess involviert sind. Aus der Gesamtdatenlage lässt sich ableiten, dass rHuKGF 
ein Potenzial als Therapeutikum bei der Behandlung des Lungenemphysems hat. 
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